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It is estimated that a total of 250 million people, or 1 out of 20 people between the ages of 
15 and 64 years, used an illicit drug in 2014 (World Drug Report, 2016). Approximately one 
in ten people who use illicit drugs is suffering from a form of a drug use disorder, including 
drug dependence. Almost half of people with drug dependence inject drugs and of them 
more than 10% are living with HIV, and the majority are infected with hepatitis C. Drug use 
disorders are a major global health problem. 
 
Drug use disorders are a serious health issue, with a significant burden for individuals 
affected and their families. There are also significant costs to society including lost 
productivity, security challenges, crime, increased health care costs, and a myriad of 
negative social consequences. The social cost of illicit drug use is estimated at up to 1.7% 
of GDP in some countries (World Drug Report, 2016). Caring for individuals with drug use 
disorders places a heavy burden on public health systems of Member States and therefore 
improving treatment systems by making them the best they can be. This would undoubtedly 
benefit not only the affected individuals, but also their communities and the whole society.    
 
After many years of medical research, it is clear that drug dependence is a complex 
multifactorial biological and behavioral disorder. Scientific advances are making it possible 
to develop treatments that help normalize brain functioning of affected individuals and 
support them in changing their behavior. Offering treatments based on the scientific 
evidence is now helping millions of affected individuals to regain control over their lives.  
 
Unfortunately, outdated views about drug use disorders persist in many parts of the world. 
Stigma and discrimination that is commonly applied to drug dependent individuals and to 
professionals working with them have significantly compromised the implementation of 
quality treatment interventions in this area, undermining the development of treatment 
facilities, the training of health professionals and the investment in recovery programmes. 
Even though the evidence clearly shows that drug use disorders are best managed within a 
public health system, similarly to other medical problems such as HIV infection or 
hypertension, the inclusion of treatment of substance and drug use disorders in the health 
care system is still very difficult in many countries where a huge gap exists between science, 
policy and the clinical practice.  
 
In some countries drug use disorders are still seen as a primarily criminal justice problem, 
and agencies of the Ministry of Interior, Ministry of Justice or Ministry of Defense are still 
responsible for affected individuals, without the supervision or engagement of the Ministry 
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of Health. Using only law enforcement strategies and methods is unlikely to result in 
sustained positive effects. Only treatment that has at its core an understanding of drug 
dependence as a primarily multifactorial biological and behavioral disorder, that can be 
treated using medical and psychological approaches, can improve chances of a recovery 
from the disorder and reduce (drug-)related consequences.  
 
Currently, UNODC showed in the World Drug Report that at a global level only 1 out of 6 
people in need of drug dependence treatment has access to treatment programmes; only 1 
out of 11 in Latin America and 1 out of 18 in Africa. Treatment in many countries is only 
available in the large cities but not in rural areas. Unfortunately, in many places available 
treatment is often not effective, not supported by the scientific evidence, and sometimes not 
in line with human rights principles. This is also the case in highly developed countries where 
availability of evidence-based treatment programmes is often insufficient.  
 
 
1.2 Drug Use Disorders 
 
Using narcotic drugs and psychotropic substances without medical supervision, is 
associated with significant health risks. For this reason, the production, sale, distribution and 
use of these substances have been regulated under the control of the international treaties 
(Conventions of 1961, 1971, 1988), with the aim to avoid negative consequences that could 
significantly undermine health and security.  
 
Approximately 10% of individuals who begin to use drugs will over time develop changes in 
their behavior and other symptoms that constitute a Drug Use Disorder (either harmful drug 
use or drug dependence in the ICD-10 classification system).  
 
At the core of the drug dependence syndrome is the strong and overpowering desire to take 
the drug, an inability to control the consumption and the amount of drugs taken  resulting in 
a disproportionate amount of time spending on excessive drug-related activities. Over time, 
the use of a drug takes on a much higher priority for a given individual, displacing other 
activities that once had greater value. Individuals with this disorder often lose interest in and 
neglect their family and social life, education, work and recreation. They may engage in 
high-risk behaviors and continue to use drugs despite the knowledge of recurrent social 
and/or interpersonal problems resulting from drug use. Finally, some drugs may produce 
over time a decrease in effects to the same repeated dose of a drug or tolerance, and a 
withdrawal syndrome - a set of characteristic adverse symptoms, when the amount of drug 
consumed is reduced or drug use has stopped. The desire to take the drug can persist, or 
easily be reactivated, even after a long period of abstinence. 
 
At the basis of these symptoms and behaviors is the disruption of neuronal pathways in 
brain areas that regulate motivation and mood, experience of pleasure and well-being, 
memory and learning, and the ability to suppress unwanted impulses.  
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The scientific community now has a complex understanding of how these disruptions in 
brain functioning result in the development of drug use disorders. First, hereditary or genetic 
factors play a role in passing on the increased risk of dependence to the next generation. 
This genetic risk is evidenced by different responses to the initial doses of drugs seen in 
individuals at risk; they show more positive effects, less negative effects, and the ability to 
tolerate much higher doses than seen in individuals without the genetic risk factors. 
Nevertheless the genetic risk can be modified by early life experiences, which can have 
protective but also detrimental effects. Early life trauma, deprivation, and persistent stress 
can make the individual more vulnerable to develop abnormal effects on the brain following 
early drug exposure. In vulnerable individuals, the exposure to drugs triggers mechanisms 
of pathological reward learning and interferes with previously learned responses to other 
behaviors and rewards, such as social interactions or food. This new type of learned 
response is very stable and can persist for life, similarly to other learned behaviors such as 
riding a bicycle.  
Previously neutral environments become strongly associated with the drug experience, 
when drugs are consumed, and can later independently trigger the desire for the drug and 
stimulate drug-seeking behavior. The desire for drugs can also be triggered by the exposure 
to stress or even small amounts of other intoxicants such as alcohol. Over time the 
memories related to drug experiences become very strong and persistent. The desire to use 
can become easily triggered whereas the ability to control and suppress the impulse to use 
becomes weaker, so that the affected individual may resume drug use despite the prior 
strong desire not to do so.   
 
As a consequence, the abnormal brain functioning in affected individuals predisposes them 
to make decisions with disastrous consequences to their own health and well-being and also 
the well-being of their families and communities, including to engage in behaviors that are 
illegal or that they would have previously considered unethical or immoral, either to purchase 
drugs or under the influence of them. 
 
Scientific advances and efforts of educating the general public are beginning to change the 
perceptions of drug use disorders throughout Member States and civil society. There is a 
greater recognition that drug use disorders are a complex health problem with psychosocial, 
environmental, and biological determinants, which need a multidisciplinary and 
comprehensive response from different institutions working together. Many policymakers 
and the general public are beginning to see that drug dependence is not simply a “self-
acquired bad habit” but rather a result of a long series of biological and environmental 
factors, disadvantages and adversities, that can be prevented and treated. Risk factors in 
both developed and in developing countries are being recognized. Early childhood neglect 
and abuse, the lack of strong family supports, impaired parenting, the lack of emotional 
support and personal engagement of teachers, household dysfunction, social exclusion and 
isolation contribute to the development of mental health problems and drug dependence in 
many communities. In other communities, these problems are compounded by exposure to 
extreme poverty, degraded neighborhoods, homelessness, displacement, exploitation, 
violence, hunger and poor working conditions and work overload. 
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In addition to the symptoms of this complex disease, individuals with severe drug use 
disorders more often than not develop additional medical or psychiatric problems. Those 
who inject drugs are likely to be exposed to blood-borne infections (HIV – Human 
Immunodeficiency Virus, HCV – Hepatitis C Virus) and TB – Tuberculosis, to carry a high 
risk of cardiovascular and liver problems, to have an increased incidence of traffic and other 
accidents, and to more frequently experience violence. Individuals with drug dependence 
have a much lower life expectancy. For example, the mortality rate of people with opioid 
dependence is significantly higher than the rate expected in the general population and 
death occurs more often at a young age. Opioid dependence was estimated to account for 
0.37% of global DALYs (Disability-adjusted life years) in 2010, a 73% increase on DALYs 
estimated in 1990 (Degenhardt et al. 2014). Overdose, HIV/AIDS, Hepatitis C, unintentional 
injures (accidents and violence), cardiovascular diseases and suicide are the most frequent 
causes of death due to drug use. The relationship between psychiatric and substance use 
disorders is very complex. Often a separate psychiatric disorder exists prior to the onset of 
substance use, putting affected individuals at greater risk of developing drug use disorders. 
Psychiatric disorders may also develop secondary to the drug use disorder, due in part to 
biological changes in the brain resulting from chronic drug use. The risk of developing drug 
dependence and psychiatric complications is particularly high in children and young adults 
who get exposed to the effects of drugs before their brain can fully mature, a process that 
usually occurs during the mid-twenties.  
 
Because drug use disorders are generally chronic in nature, the risk of relapse to drug use 
persist for many years, in some cases even after many years of complete abstinence from 
drugs. The implication of this is that therapeutic services have to be ready to work with drug 
use disorder patients over the long term, maintaining contact and offering monitoring for 
years, sometimes for the entire life. This is similar to the system of care for patients with 
other chronic diseases (diabetes, asthma, high blood pressure) that are prepared to deal 
with periods of symptom remission but also exacerbation, delivering the intensity of 
interventions to match the severity of the presented problem without the expectation that a 
condition can be completely cured after a short-term treatment episode. Recognizing the 
nature of chronicity and the relapsing course of drug users, ongoing drug use does not imply 
that the treatment is ineffective and therefore useless. On the contrary, appropriate 
treatment delivered repeatedly despite ongoing use or intermittent relapses in drug use is 
essential to guarantee an improved quality and duration of life in spite of the persistent and 
serious health problems while minimizing harmful effects to both the drug users and the 
community, and maximizing the chances of a long and healthy life.   
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1.3 New Trends in Drug Use  
 
Traditionally drugs were mainly plant-derived substances such as cocaine, heroin and 
cannabis, consumed in the region in which they were grown or along trade routes to their 
final market. Increased global trade and travel is globalizing the market in plant-based 
substances that were previously specifically focused in different regions.  
In recent decades, more synthetic psychoactive substances (NPS) including amphetamines 
and related stimulants synthetized in illicit laboratories have become more widely available 
and are being produced and consumed in every region. A significant proportion of substance 
use disorders due to the non-medical use of prescription drugs that are classified as 
controlled substances such as synthetic pain medicines, sedative hypnotics, or 
psychostimulants. The increase in the last 10 years in the use of strong opioids in the 
management of chronic pain in some parts of the world has resulted in a dramatic increase 
in opioid overdose deaths.  
 
In order to avert legal efforts in controlling the distribution of dangerous psychoactive 
substances based on the scheduling of specific compounds, hundreds of new psychoactive 
substances are synthesized, distributed, and used every year with unpredictable and often 
dramatic adverse consequences in users. The production and trafficking of NPS, that can 
often be purchased via the internet, makes their monitoring and control even more difficult. 
Few countries have an early warning system in place to collect and share information on 
these new substances.  
 
The result of these changes is that many countries are seeing a change in drug use patterns; 
away from more traditional plant-based substances towards synthetic compounds, 
prescription medicines, or other plant-based substances. While globally opioids continue to 
represent the major threat to public health, this is now being more closely followed by 
amphetamine-type stimulants (UNODC World Drug Report, 2016).  
 
Often  health care systems are struggling to respond appropriately to the emergence of new 
behavioral and medical problems in drug users. For example, in parts of the world where 
opioids were previously seldom used, health systems do not usually have the capacity to 
deliver medically assisted treatment of opioid use disorders, such as opioid agonist 
maintenance treatment. Similarly, in parts of the world where the treatment system has 
mainly focused on opioid use disorders, there are now large increases in the prevalence of 
psychostimulant use disorders and treatment systems, that have been developed to 
manage opioid–related disorders are not able to respond appropriately to the new type of 
patients, for whom evidence-based psychosocial treatment is the main effective 
intervention. In addition, many regions are seeing new treatment populations such as young 
people with poly-drug use, pregnant women, children with drug use problems, elderly drug 
users, people with medical comorbidities such as HIV, TB, and HCV, people with psychiatric 
comorbidities such as anxiety, depression, personality disorders and psychosis, people with 
primary prescription drug problems, and people primarily using new psychoactive 
substances. The resulting combination of changing patterns of substance use and changing 
populations of substance users results in challenges for many health care systems to adapt 
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in a timely, effective and efficient way, which would require urgent investment in treatment 
programmes and human resources. 
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1.4 International Treatment Standards 
 
To assist Member States in the development of appropriate responses and evidence based 
services for drug use disorders, in 2009 UNODC and WHO jointly created a Global 
Programme on Drug Dependence Treatment and Care. The main purpose of this inter-
agency programme is to disseminate good practice-examples informed by science and 
ethical principles in this field, guaranteeing for drug dependent people the same quality 
standards and opportunities that are provided by the health system for any other chronic 
diseases.  
 
The International Standards for the Treatment of Drug Use Disorders (Standards) were 
prepared to support Member States in the development and expansion of treatment services 
that offer effective and ethical treatment. The goal of such treatment is to reverse the 
negative impact that persisting drug use disorders have on the individual and to help 
individuals achieve a recovery from the disorder as fully as possible and help them to entirely 
participate in society as a member of their community.   
 
The UNODC-WHO International Standards for the Treatment of Drug Use Disorders 
summarize the currently available scientific evidence on the effective treatment interventions 
and approaches, and set out a framework for their implementation consistent with principles 
of health care more broadly. This document identifies major components and features of an 
effective drug treatment system, with a description of evidence-based treatment 
interventions to match the needs of people affected in different stages of the disease, in a 
consistent manner consistent with the treatment of any chronic disease.  
 
In the past, UNODC and WHO developed Principles of Drug Dependence Treatment 
(Principles) which constitute an overarching policy and guidance. The Standards include a 
description of specific practices and procedures that help establish, maintain and support 
the Principles. The Standards provide rules or minimum requirements for clinical practice, 
generally accepted principles of patient management in any healthcare system.  
 
This work builds on and recognizes the work of many other organizations (e.g. EMCDDA, 
CICAD, NIDA, SAMHSA) which have previously developed standards and guidelines on 
various aspects of drug treatment and participated in the drafting of the present Standards 
document.  
 
It is our hope that the present Standards will guide policy makers and social or health 
practitioners worldwide in the development of policies, drug treatment services, and human 
resources to support therapeutic services. The Standards will be also helpful in evaluation 
and ongoing improvement of services. It is our hope that new policies and treatment systems 
developed with the help of these Standards will be a truly effective investment in the future 
of people affected by drug use disorders, their families, and communities.  
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Chapter 2: Key Principles and Standards for the Treatment of 
Drug Use Disorders 
 
 
Drug Use Disorders can be effectively treated using a range of pharmacological and 
psychosocial interventions. The effectiveness of the majority of these interventions has been 
tested using scientific methods developed for the treatment of other medical disorders.  
 
In the management of substance use disorders, the goals of treatment are to: 
 1) reduce drug use and cravings for drug use,  
2) improve health, well-being and social functioning of the affected individual, and  
3) prevent future harms by decreasing the risk of complications and relapse. 
 
Many interventions that are commonly used in the management of substance use disorders 
do not meet accepted scientific standards of clinical efficacy. Such interventions may be 
ineffective or even harmful, or it may be that the necessary clinical trials may not have been 
conducted, and the effectiveness of the treatment is unknown. Resources available to work 
with affected individuals are limited, therefore priorities for resource allocation must be 
carefully evaluated against the goals of treatment.  
 
In addition to these criteria that have a clinical effectiveness focus, the treatment of 
substance use disorders should meet the common standards of all health care:  
1. be consistent with UN Declaration of Human Rights and existing UN Conventions,  
2. promote personal autonomy, 
3. promote individual and societal safety.  
 
The International Standards for the Treatment of Drug Use Disorders define a set of 
requirements that must be in place before any form of outreach, treatment, rehabilitation, or 
recovery services may be considered safe and effective care, regardless of the treatment 
philosophy that is used or the setting it is used in. This is critically important, because 
individuals with drug use disorders deserve nothing less than ethical and science-based 
standards of care that are similar to the standards used in treatment of other chronic 
diseases. 
 
Principle 1. Treatment must be available, accessible, attractive, and appropriate  
 
Description: Drug use disorders can be treated effectively in the majority of cases if people 
have access to a wide-range of services that cover the continuum of issues that patients 
may face. Treatment services must match the specific requirements of the individual patient 
at the specific phase of their disorder. These services include outreach, screening and brief 
interventions, inpatient and outpatient treatment, medical and psychosocial treatment 
(including treatment of common comorbidities), long-term residential treatment, 
rehabilitation, and recovery-support services. These services should be affordable, 
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attractive, available in both urban and rural settings, and accessible with a wide range of 
open hours and a minimal waiting time. All barriers that limit the accessibility of appropriate 
treatment services should be minimized. Services should not only offer treatment for the 
drug use disorders per se, but also provide social support and protection and general 
medical care. The legal framework should not discourage people with drug use disorders 
from attending treatment programmes. The treatment environment should be friendly, 
culturally sensitive and focus on the specific clinical needs and the level of preparedness of 
each patient, thus providing an environment that encourages rather than deters individuals 
from attending the programme.  
 
Standards: 
1.1. Essential treatment services for drug use disorders should be available at 
different levels of health systems: from primary health care to tertiary health 
services with specialized treatment programmes for drug use disorders. 
1.2. Essential treatment services include outreach services, brief psychosocial 
interventions, diagnostic assessment, outpatient psychosocial treatment, 
evidence-based pharmacological treatment, services for management of drug-
induced acute clinical conditions such as overdose, withdrawal syndromes and 
drug-induced psychoses, inpatient services for the management of severe 
withdrawal, long-term residential services, treatment of common comorbidities.  
1.3. Essential treatment services for drug use disorders should be within reach of 
public transport and accessible to people living in urban and rural areas. 
1.4. Low threshold and outreach services, as part of a continuum of care, are needed 
to reach the ‘hidden’ populations most affected by drug use, often non-motivated 
to treatment or relapsing after a treatment programme.  
1.5. Within a continuum of care, people with drug use disorders should have access 
to treatment services through multiple entry points. 
1.6. Essential treatment services for drug use and drug-induced disorders should be 
available during a sufficiently wide range of opening hours to ensure access to 
services for individuals with employment or family responsibilities.  
1.7. Essential treatment services should be affordable to clients from different socio-
economic groups and levels of income with minimized risk of financial hardship 
for those requiring the services. 
1.8. Treatment services should be gender-sensitive and tailored to the needs of 
women including specific child-care needs and needs in pregnancy.  
1.9. If not otherwise accessible, affordable or available, treatment services should 
provide access to social support, general medical care and the management of 
co-morbid health conditions.  
1.10. Treatment services for drug use disorders should be oriented towards the needs 
of the populations they serve, with due respect to cultural norms and involvement 
of service users in the service design, delivery and evaluation.  
1.11. Information on availability and accessibility of essential treatment services for 
drug use disorders should be easily accessible through multiple sources of 
information including internet, printed materials and open access information 
services.  
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Principle 2: Ensuring ethical standards of care in treatment services 
 
Description: Treatment of drug use disorders should be based on universal ethical 
healthcare standards – including the respect for human rights and the patient’s dignity. This 
includes responding to the right to enjoy the highest attainable standard of health and well-
being, ensuring non-discrimination, and removing stigma. Treatment decisions, including 
when to start and stop treatment, and what kind of treatment, should be made by the 
individual, to the extent that they have capacity to do so. Treatment should not be forced or 
against the will and autonomy of the patient. The consent of the patient should be obtained 
before any treatment intervention. Accurate and up-to-date medical records should be 
maintained and the confidentiality of treatment records should be guaranteed. Registration 
of patients entering treatment outside the health records should not be permitted. Punitive, 
humiliating or degrading interventions should never be used. The individual affected should 
be recognized as a person suffering with a health problem and deserving treatment similar 
to patients with other psychiatric or medical problems. 
 
Standards:  
2.1 Treatment services for drug use disorders should in all cases respect the human 
rights and the dignity of service users, and humiliating or degrading interventions 
should never be used.  
2.2 Informed consent should be obtained from a patient before initiating treatment 
and guarantee the option to withdraw from treatment at any time.  
2.3 Patient data should be strictly confidential, and registration of patients entering 
treatment outside the health records should not be allowed. Confidentiality of 
patient data should be ensured and protected by legislative measures and 
supported by appropriate staff training and service rules and regulations.  
2.4 Staff of treatment services should be properly trained in the provision of treatment 
in full compliance of ethical standards and human rights principles, and show 
respectful, non-stigmatizing and non-discriminatory attitudes towards service 
users.  
2.5 Services procedures should be in place which require staff to adequately inform 
patients of treatment processes and procedures, including the right to withdraw 
from treatment at any time.  
2.6 Any research conducted in treatment services involving human subjects should 
be subject to review of human research ethical committees, and participation of 
service users in the research should be strictly voluntary with informed written 
consent ensured in all cases.  
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Principle 3: Promoting treatment of drug use disorders by effective coordination 
between the criminal justice system and health and social services  
 
Description: Drug use disorders should be considered primarily as health problems rather 
than criminal behaviors and as a general rule, drug users should be treated in the health 
care system rather than in the criminal justice system. Even though individuals with drug 
use disorders may commit crimes, these are typically low-level crimes used to finance the 
drug purchase, and this behavior typically stops with the effective treatment of the drug use 
disorder. Because of that, the criminal justice system should collaborate closely with the 
health and social system to encourage treatment in the health care system over criminal 
prosecution or imprisonment. Law enforcement, court professionals and penitentiary system 
officers should be appropriately trained to effectively engage with treatment and 
rehabilitation efforts. If prison is warranted, treatment should also be offered to prisoners 
with drug use disorders during their stay in prison and after their release as effective 
treatment will decrease the risk of reoffending following their release. Continuity of care after 
the release is of vital importance and should be assured or facilitated. In all justice-related 
cases people should be provided with treatment and care of an equal standard to treatment 
offered in the community.  
 
Standards: 
3.1 Treatment for drug use disorders should be provided predominantly in health 
and social-care systems, and effective coordination mechanisms with the 
criminal justice system should be in place to facilitate access to treatment and 
social services of people in contact with the criminal justice system. 
3.2 Treatment of drug use disorders should be available to offenders with drug use 
disorders and, where appropriate, be a partial or complete alternative to 
imprisonment or other penal sanctions.  
3.3 Treatment of drug use disorders as an alternative to incarceration or provided 
within criminal justice settings should be supported by appropriate legal 
frameworks.  
3.4 Criminal justice settings should provide opportunities for individuals with drug 
use disorders to receive treatment and health care that are available in health 
and social care systems in a community.  
3.5 Treatment interventions for drug use disorders should not be imposed on 
individuals with drug use disorders in criminal justice system against their will. 
3.6 Essential prevention and treatment services should be accessible to 
individuals with drug use disorders in criminal justice settings, including 
prevention of transmission of blood-borne infections, pharmacological and 
psychosocial treatment of drug use disorders and comorbid health conditions, 
rehabilitation services and the linking with community health and social 
services in preparation for their release.  
3.7 Appropriate training programmes for criminal justice system staff, including law 
enforcement and penitentiary system officers and court professionals should 
be in place to ensure recognition of medical and psychosocial needs 
associated with drug use disorders and to support treatment and rehabilitation 
efforts. 
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3.8 Treatment of drug use disorders in the criminal justice system should follow 
the same evidence-based guidelines and ethical and professional standards 
as in the community.  
3.9 Continuity of treatment for drug use disorders should be ensured in all cases 
by effective coordination of health and social services in communities and 
criminal justice settings.  
  
Principle 4: Treatment must be based on scientific evidence and respond to specific 
needs of individuals with drug use disorders 
 
Description: The cumulative body of scientific knowledge on the nature of drug use 
disorders and their treatment should guide interventions and investments in the treatment 
of drug use disorders. The same high standards required for the approval and 
implementation of pharmacological or psychosocial interventions in other medical 
disciplines should be applied to the treatment of drug use disorders. As a general rule, only 
the pharmacological and psychosocial methods that have been demonstrated effective by 
science or agreed upon by the international body of experts should be applied. Where there 
is reason to believe that other treatment approaches may be useful, they should be provided 
in the context of clinical trials. The duration and the intensity (dose) of the intervention should 
be in line with evidence-based guidelines. Multidisciplinary teams should integrate different 
interventions tailored to each patient. Organization of treatment for drug use disorders 
should be based on a chronic care philosophy as opposed to an acute care philosophy. 
Severe drug use disorders are similar in their course and prognosis to other chronic 
diseases such as diabetes, HIV, cancer, or hypertension. A long-term model of treatment 
and care is most likely to promote a long and healthy life. Existing interventions should be 
adapted to the cultural and financial situation of the country without undermining the core 
elements identified by science as crucial for effective outcomes. Traditional treatment 
systems may be unique to a particular country or setting and may have limited evidence of 
their effectiveness beyond the experience of patients and their clinicians. Such systems 
should learn from and adopt as much as possible of the existing evidence-based 
interventions into their programmes and efforts should be made to formally evaluate whether 
such treatments are effective and/or carry acceptable risks.  
 
Standards:  
4.1 Resource allocation in the treatment of drug use disorders should be guided 
by existing evidence of the effectiveness and cost-effectiveness of prevention 
and treatment interventions for drug use disorders. 
4.2 A range of evidence-based treatment interventions of different intensity 
should be in place at different levels of health and social systems with 
appropriate integration of pharmacological and psychosocial interventions.   
4.3 Health professionals at primary health care should be trained in the 
identification and management of the most prevalent disorders due to drug 
use. 
4.4 In the treatment of drug use disorders health professionals in primary health 
care should be supported by specialized services for substance use 
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disorders at advanced levels of health care, particularly for the treatment of 
severe drug use disorders and patients with comorbidities.  
4.5 Where possible, the organization of specialized services for drug use 
disorders should be based on multidisciplinary teams adequately trained in 
the delivery of evidence-based interventions with competencies in addiction 
medicine, psychiatry, clinical psychology and social work.  
4.6 The duration of treatment should be determined by individual needs and 
there should be no pre-set limits in the duration of treatment that can’t be 
modified according to the patient’s clinical needs. 
4.7 Training of health professionals in the identification, diagnosis and evidence-
based treatment of drug use disorders should be in place at different levels 
of education including university curricula and programmes of continuing 
education.  
4.8 Treatment guidelines, procedures and norms should be regularly updated in 
accordance with accumulated evidence of effectiveness of treatment 
interventions, knowledge about the needs of patients and service users and 
results of evaluation research.  
4.9 Treatment services and interventions for drug use disorders should be 
adapted for relevance to the socio-cultural environment in which they are 
applied.   
4.10 Treatment services should attempt to measure their performance against 
performance standards for comparable services. 
4.11 The development of new treatments should be conducted through the clinical 
trial process and overseen by an authorized human research ethics 
committee.  
 
Principle 5: Responding to the needs of specific populations  
 
Description: Several subgroups within the larger population of individuals affected by drug 
use disorders require special consideration and often specialized care. Groups with specific 
needs include, but are not limited to: adolescents, the elderly, women, pregnant women, 
children, sex workers, sexual and gender minorities, ethnic and religious minorities, 
individuals involved with the criminal justice system and individuals that are socially 
marginalized. Working with those special groups requires differentiated and individualized 
treatment planning that considers their unique vulnerabilities and needs. For some of these 
subgroups, special considerations will need to be addressed directly in every setting on the 
treatment continuum.  
 
In particular, children and adolescents should not be treated in the same setting as adult 
patients, and should be treated in a facility able to manage other issues such patients face, 
and should encompass broader health, learning, and social welfare context in collaboration 
with family, schools and social services. Similarly, women entering treatment should have 
special protection and services. Women with drug use disorders are more vulnerable to 
domestic violence and sexual abuse, and their children may also be at risk of abuse, 
therefore a liaison with social agencies protecting women and children is helpful. Women 
may require women-focused treatment in a safe single-sex setting to obtain maximum 
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benefit. Treatment programmes should be able to accommodate children’s needs and to 
allow parents caring for children to receive treatment as well, and support good parenting 
and child care practices. Women may need training and support on issues such as sexual 
health and contraception.  
 
Standards:  
5.1 The needs of specific population groups are reflected in service provision and 
treatment protocols, including the needs of women, adolescents, children, 
pregnant women, ethnic minorities and marginalized groups such as the 
homeless.   
5.2 Special services and treatment programmes should be in place for adolescents 
with substance use disorders to address the specific treatment needs associated 
with this age and to prevent contacts with patients in more advanced stages of 
drug use disorders. Separate settings for treatment of adolescents should be 
considered whenever possible.  
5.3 Treatment services and programmes for drug use disorders should be tailored to 
the needs of women and pregnant women in all aspects of their design and 
delivery, including location, staffing, programme development, child friendliness 
and content. 
5.4 Treatment services should be tailored to the needs of people with drug use 
disorders from minority groups, and cultural mediators and interpreters should be 
available whenever necessary in order to minimize cultural and language barriers.   
5.5 A package of social assistance and support should be integrated into treatment 
programmes for people with drug use disorders who are homeless, or 
unemployed.  
5.6 Outreach services should be in place to establish contact with people who may not 
seek treatment because of stigma and marginalization.  
 
 
Principle 6: Ensuring good clinical governance of treatment services and 
programmes for drug use disorders 
 
Description: Good quality and efficient treatment services for drug use disorders require 
an accountable and effective method of clinical governance. Treatment policies, 
programmes, procedures and coordination mechanisms should be defined in advance and 
clarified to all therapeutic team members, administration, and the target population. Service 
organization should reflect current research evidence and be responsive to the service 
user’s needs. Treating people with drug use disorders who often have multiple psychosocial 
and sometimes physical impairments is challenging, both for individual staff and 
organizations. Staff attrition in this field is recognized and organizations should have in place 
a variety of measures to support their staff and encourage the provision of good quality 
services.  
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Standards:  
6.1 Treatment policies for drug use disorders should be based on the principles of 
universal health coverage, consistent with the best available evidence and 
developed with the active involvement of key stakeholders including the target 
populations, community members (families), and non-governmental organizations.   
6.2 Written service policy and treatment protocols should be available, known to all 
staff and guide delivery of treatment services and interventions.  
6.3 Staff working in specialized services for drug use disorders should be adequately 
qualified, and receive ongoing evidence-based training, certification, support and 
clinical supervision. Clinical supervision, mentoring and other forms of support are 
needed for the prevention of burnout among staff members. 
6.4 Policies and procedures for staff recruitment and performance monitoring should 
be clearly articulated and known to all.  
6.5 A sustainable source of funding should be available at adequate levels and proper 
financial management and accountability mechanisms should be in place. 
Whenever possible, resources for ongoing staff education, for the evaluation of 
service quality and performance should be included in the relevant budget.  
6.6 Services for the treatment of drug use disorders should network and link with 
relevant general and specialized health and social services in order to provide a 
continuum of comprehensive care to their patients.     
6.7 Adequate record systems should be in place to ensure accountability and 
continuity of treatment and care.   
6.8 Service programmes, rules and procedures should be periodically revised, and 
mechanisms of continuous feed-back, monitoring and evaluation should be 
developed.  
6.9 Patterns of drug use and related health consequences and comorbidities should 
be regularly monitored and results made available to help the planning and 
governance of treatment services.   
 
 
Principle 7. Treatment policies, services, and procedures should support an 
integrated treatment approach, and linkages to complementary services must be 
constantly monitored and evaluated 
 
Description: As a response to a complex and multifaceted health problem, comprehensive 
treatment systems must be developed to facilitate effective treatment of drug use disorders 
and associated health-care problems. Where possible, a treatment system should include 
and coordinating teams should engage psychiatric, psychological and mental health care, 
social services (for housing and job skills/employment and, if necessary, legal assistance), 
other specialist health care (such as services for HIV, HCV, TB and other infections). The 
treatment system must be constantly monitored, evaluated and adapted. This requires 
planning and implementation of services in a logical, step-by-step sequence that insures the 
strength of links between (a) policy, (b) needs assessment, (c) treatment planning, (d) 
implementation of services, (e) monitoring of services, (f) evaluation of outcomes and (g) 
quality improvements. 
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Standards:  
7.1 Treatment policies for drug use disorders should be formulated by relevant 
governmental authorities on the principles of universal health coverage, best 
available evidence and with active involvement of key stakeholders including 
the target populations, community members (families), non-governmental 
organizations and religious organizations.   
7.2 Links between drug use prevention, drug dependence treatment, and 
prevention of health and social consequences of drug use should be 
established and operational. 
7.3 Treatment planning should be based on estimates and descriptions of the 
nature and the extent of the drug problem, as well as of the characteristics of 
the population in need.   
7.4 Roles of national, regional and local agencies in different sectors responsible 
for the delivery of treatment for drug use disorders and rehabilitation should be 
defined and mechanisms for effective coordination should be established. 
7.5 Quality standards for drug treatment services should be established and 
compliance should be required for accreditation. 
7.6 Mechanisms of clinical governance, monitoring and evaluation should be in 
place including clinical accountability, continuous monitoring of the patient’s 
health and well-being, and intermittent external evaluation.  
7.7 Information on the number, type, and distribution of services available and 
used within the treatment system should be monitored for planning and 
development purposes.  
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Chapter 3: Treatment Modalities and Interventions 
 
 
3.1 Community-Based Outreach 
 
3.1.1 Brief Definition and Description of the Setting 
Community-based outreach services approach and engage with people who use drugs in 
their community who are not currently receiving treatment, because of the unavailability, 
inaccessibility or unacceptability of existing services. Outreach also targets individuals who 
are affected by the drug use of others (e.g. sexual partners, needle-sharing partners, etc.). 
Being based or coming from the community they serve, outreach workers are often 
indigenous to the local community. They are familiar with the drug use subculture or may 
even themselves be former or occasional drug users. Outreach workers and peer workers 
typically carry out a set of specific education and support strategies devised and 
implemented by members of that same subculture, community or group of people.  
 
Outreach acknowledges the influence of social networks on individuals experiencing drug 
use disorders and recognizes that these networks are important determinants of negative 
health and social outcomes and utilize them to influence and promote healthy behavior. 
Many outreach models use a mixture of individual and network-based interventions. 
 
3.1.2. Target population 
 
Outreach activities primarily target individuals with harmful use of drugs and/or dependence 




The objectives of community-based outreach are to identify affected populations, engage 
them, provide community-based care, and if necessary to refer to more intensive treatment 
modalities.  
 
Outreach work is possible in any community, including online “virtual” communities, with the 




Given the often clandestine nature of drug using populations, outreach workers should be 
knowledgeable of the local communities they serve and should have access to mental health 
services and other supports themselves. They require adequate basic training:  
• to establish trust and recognize sources of accurate information, 
• in recognizing and responding to crisis situations, 
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• in relevant health conditions: 
o recognition and response to overdose, 
o prevention and treatment of HIV, TB, Hepatitis, 
o mental health and suicidal behavior.  
• about health and social services in the community. 
 
An outreach programme is dependent on their front-line workers, key assets that require 
adequate periodic training and access to mental health services and other supports 
themselves. 
 
The programme itself should be flexible, adaptive, have a clear mission statement, 
mechanisms for monitoring and evaluation, as well as clear and relevant documentation.  
 
3.1.5 Treatment Models and Methods 
 
Outreach programmes vary enormously according to the local situation but typically the 
following ‘core services’ should be provided:  
1. Information and linkage to services caring for basic needs (safety, food, shelter, 
hygiene and clothing)  
2. Needle exchange and condom distribution  
3. HIV/HCV testing and counselling 
4. Hepatitis B vaccination 
5. Education on drug-effects and risks involved in drug use  
6. Basic assessment of substance use disorders  
7. Brief Intervention to motivate change in substance use  
8. Referral to treatment for substance use disorders 
9. Basic counselling/social support 
10. Referral to health care services as needed 
11. Overdose prevention services including emergency naloxone 
 
3.1.6 Strength of Evidence 
 
The effectiveness of outreach programmes, which involve risk reduction interventions 
targeting overdose, HIV, viral hepatitis and other infections, is supported mostly by quasi-
experimental and large observational studies1.  
 
  
                                            
1 WHO 
http://www.who.int/mental_health/mhgap/evidence/resource/substance_use_q6.pdf?ua=1 
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3.1.7 Recommended standards for outreach 
 
Policy makers 
• There is detection of intoxicated persons requiring treatment for intoxication and 
withdrawal syndromes in public spaces. 
• Agreements between health and law enforcement personnel are in place and there is a 
mutual understanding of the benefits of outreach work.  
• ‘Core interventions’ (see above) to reduce the negative health and social consequences 
of drug use and dependence are available. 
• There is promotion of early intervention for drug related problems. 
• There is promotion of early intervention among specific population subgroups (e.g., 
pregnant women, sex workers, youth, homeless people). 
• There is promotion of voluntary seeking for the treatment of drug related problems. 
• Information about assessment procedures and treatment resources is distributed to 
individuals who are the initial contact points for potential patients. 
• Procedures exist for counselling family members, employers, and those who seek 
assistance in recruiting drug users into treatment. 
• A record of onward referral is kept to ensure continuity of clinical care. 
 
Programme managers 
• Peer outreach workers should be officially employed.  
• The work of peer outreach workers should meet accepted safety standards. 
• The service should have policies for defining what constitutes safe working conditions 
and what to do if staff feel they are in an unsafe situation.  
• Specialised care (medical, nursing, medication dispensing, psychological, 
psychotherapeutic) is always carried out by personnel with relevant qualifications and 
licences. 
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3.2 Screening, Brief Interventions, and Referral to Treatment (SBIRT) 
 
 
3.2.1 Brief Definition and Description of the Setting 
 
Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based 
practice used to identify, reduce, and prevent drug use disorders, particularly in health 
settings, which are not specialized in the treatment of drug use disorders (i.e. primary care, 
emergency care, hospitalized patients, antenatal care, social welfare services, school health 
services, prison health services, mental health facilities etc.). Screening and Brief 
Interventions (SBI) can be implemented in a rapid and cost-efficient manner that causes 







Routine screening in non-specialized health settings can support the early identification of 
individuals experiencing problems related to their drug use. For people who screen positive, 
a brief intervention, carried out in a non-judgmental and motivational style, can be effective 
in altering the trajectory of people at risk of developing drug use disorders or experiencing 
other severe negative complications related to their drug use. Screening may also identify a 
smaller subset of persons with already more significant, chronic or complex substance use 
problems who will require a more extensive assessment and referral for formal treatment.  
 
 
3.2.3 Types of clients this setting is best suited for 
 
Systematic screening of all clients is recommended in all clinical settings with a high 
prevalence of drug use. This may include: 
• General practice settings in economically disadvantaged areas 
• Mental healthcare patients 
• Hospital patients 
o Emergency room 
o Plastic surgery ward 
WHO mhGAP Evidence-Based Recommendations for Management of Drug Use Disorders in Non-
Specialized Health Settings: Brief Psychosocial Interventions 
 
Individuals using cannabis and psychostimulants should be offered brief intervention, when they are 
detected in non-specialized health care settings. Brief intervention should comprise a single session of 5-
30 minutes duration, incorporating individualised feedback and advice on reducing or stopping cannabis / 
psychostimulant consumption, and the offer of follow-up. 
 
People with ongoing problems related to their cannabis or psychostimulant drug use who do not respond 
to brief interventions should be considered for referral for specialist assessment. 
 
WHO, 2012 
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o Orthopaedic surgery ward 
• Sexual health clinics 
• Hepatitis services 
• Individuals in contact with social service and welfare agencies 
o Populations experiencing insecure housing conditions 
o Populations living and working on the street 
o Populations transitioning from institutions 
• Patients in infectious disease clinics 
 
In other settings, opportunistic screening may be based on specific complaints which can 
be associated with drug use or other features of the client that increase the possibility of 
drug use. 
 
Brief interventions are suitable for people with harmful drug use but not for people who are 
drug-dependent, who need referral to more comprehensive treatment.   
 
 




Screening tools can be grouped in two categories:  
• Self-report tools (interviews, self-report questionnaires) and  
• Biological markers (breathalyzer, blood alcohol levels, saliva or urine testing, serum 
drug testing).  
 
Self-report tools have the advantages of being physically non-invasive and inexpensive. 
A good self-report screening tool should be brief,  easy to administer and to interpret, 
address alcohol and other drugs, have an adequate clinical sensitivity and specificity for 
identifying people who need a brief intervention or referral for treatment. 
 
The accuracy of self-report can be enhanced when the patient is given the assurance of 
confidentiality, when the patient is interviewed in a setting that encourages honest reporting 
and when the patient is asked clearly worded and objective questions.  
 
The ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) is an 
evidence-based screening tool developed and recommended by the World Health 
Organization. It consists of 8 questions asking about alcohol, tobacco and drug use 
(including injecting drug use). The questions give information about hazardous, harmful or 
dependent use. It has been especially developed for a primary care setting and is 
recommended in either an interview or self-completed format (WHO, 2010). 
 
Biological markers may be useful when a patient is not able to respond to an in-person 
interview, but information is required to attain a screening result (i.e. an unconscious patient 
in intensive care). However, for conscious patients it is preferable to use a self-report 
screening tool.  




3.2.4.2 Brief Intervention 
 
A brief intervention is a structured therapy of short duration (typically 5-30 minutes) with the 
aim of assisting an individual to cease or reduce the use of a psychoactive substances or 
(less commonly) to deal with other life issues. It is designed in particular for general 
practitioners and other primary health care workers (WHO, 1994). 
 
Following a client-centered and strength-based approach patients are empowered and 
motivated to take responsibility and change their substance use behavior. If available and 
necessary, brief intervention may be extended for one or two sessions to help patients 
develop the skills and resources to change, or for a follow-up to assess if further treatment 
is required.   
 
Several basic steps should be followed for an effective brief intervention. Initially the 
practitioner will introduce the issue of drug use in the context of the patient’s health and 
wellbeing, in context of the challenge that brought them to this current situation. Since the 
patient is placed at the center of the discussion, strategies such as summarizing and 
reflection are used to provide feedback. Patients are  asked to talk about change and to set 
realistic goals. At the end of the session, practitioners summarize and provide positive 
feedback to empower patients to take responsibility for changing their behavior. 
 
The components of effective brief interventions can be summarized in the FRAMES 
framework (Miller and Rollnick, 2002): 
• Feedback is given to the individual about personal risk or impairment 
• Responsibility for change is placed on the individual 
• Advice to change is given by the provider 
• Menu of alternative self-help or treatment options is offered  
• Empathic style is used in counselling 
• Self-efficacy or optimistic empowerment is engendered 
 
WHO recommends the following 9 step approach to brief interventions following the ASSIST 
screening: 
 
1. Asking clients if they are interested in seeing their ASSIST questionnaire scores. 
2. Providing personalised feedback to clients about their scores using the ASSIST 
feedback report card. 
3. Giving advice about how to reduce risk associated with substance use. 
4. Allowing clients to take ultimate responsibility for their choices. 
5. Asking clients how concerned they are by their scores. 
6. Weighing up the good things about using the substance against the less good things 
about using the substance. 
7. Summarize and reflect on clients’ statements about their substance use with emphasis 
on the ‘less good things’.  
8. Asking clients how concerned they are by the ‘less good things’.  
9. Giving clients take-home materials to bolster the brief intervention. 




3.2.4.3 Referral to Treatment  
 
Persons who are screened and subsequently assessed as having a clinically significant 
substance use disorder or a serious co-occurring condition should be referred immediately 
for treatment to the most appropriate facility or practice. Referrals may be facilitated by 
techniques such as making the appointment at the treatment center together with the patient 
present, using ‘patient navigators’ who accompany the patient to the treatment center, and 
following up with the patient regarding their enrollment in the treatment programme. The 
most efficient referral to treatment is achieved by initiating and providing drug treatment at 
the setting where SBIRT is delivered.  
 
 
3.2.5 Criteria for programme completion and indicators of effectiveness 
 
Performance metrics for SBIRT can include rates of screenings completed by each trained 
person within the facility, the proportion of those who screened positive (unusually high or 
low numbers of positive screens may indicate a problem), the proportion of patients with 
positive screens who received at least one brief motivational intervention session, the 
proportion of patients with more serious screening results who received formal assessment 
and referral to treatment, and proportion of patients referred to treatment who initiated 
treatment. 
 
3.2.6 Rating the Strength of Evidence 
There is evidence from a small number of Randomized Clinical Trials (RTCs) that 
screening and brief intervention is effective in reducing drug use, in people who are not 





• Health care facilities with a high prevalence should systematically screen all patients 
for substance use disorders. 
• Patients in all health care settings should be screened for drug-use disorders when 
there is a clinical suspicion of drug use.  
• All health care personnel should be trained in screening, brief intervention and 
referral to treatment. 
 
  
                                            
2 WHO 
http://www.who.int/mental_health/mhgap/evidence/resource/substance_use_q1.pdf?ua=1 




• The provider has a system laid out that ensures that the method for selecting, hiring 
and training staff corresponds to valid legal norms and established internal rules. 
• The organisation has rules defined that the staff follows in cases where valid 
legislation is too general. 
• The structure and management of the organisation is defined, making competences 
for individual positions clear. 
• The provider has specified the structure and staffing needs, as well as corresponding 
job profiles and staff qualifications, taking into account the needs and current number 
of service users for service organisation. The composition and additions to the team 
correspond to these needs. 
• Prevention of work risks has been secured. 
• Cases where a patient’s rights have been violated by an employee and the 
corresponding measures that were taken are documented in personnel records. 
• Specialised care (medical, psychological, psychotherapeutic, social, educational 
etc.) is always carried out by personnel with relevant qualifications and licences. 
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3.3 Short-Term In-Patient or Residential Treatment 
 
 
3.3.1 Brief definition and description of the setting  
 
The short-term inpatient (or residential) treatment setting is an environment in which 24 hour 
care is available at an intensity which is capable of managing the symptoms and potential 
complications likely to occur in the days and initial weeks following the cessation of drug 
use, including the drug withdrawal syndrome.  
 
Short-term inpatient treatment provides an opportunity to cease drug use with minimal 
discomfort and risk to health and offers both a temporary reprieve from the environmental 
stressors in a person’s life, and an opportunity to receive some psychosocial support, which 
may become the start of an ongoing treatment process. The length of stay varies from 1 to 
4 weeks according to the local practices and the clinical situation. Given that the drug 
withdrawal syndrome and its treatment can pose significant health risks, short-term 
residential treatment requires a higher degree of medical supervision than long-term 




The goals of short-term residential treatment are to facilitate the initial cessation of drug use 
and to motivate patients to continue some further treatment after the short-term residential 
treatment. This ongoing treatment may be psychological (i.e. a structured psychological 
support such as CBT, MET, CRA or CM), social (i.e. employment of housing programmes), 
or pharmacological (such as naltrexone for opioid dependence, or methadone or 
buprenorphine maintenance treatment).  
 
Medically assisted detoxification can also be accomplished on an outpatient basis, which is 
less resource intensive, but the rates of completion of detoxification are lower (WHO, 2009). 
The risk of relapse is high following any form of detoxification, which can result in an 
increased risk of overdose post treatment, particularly in opioid users.  
 
 
3.3.3 Target population 
 
The typical target population are people with drug dependence likely to experience 
significant withdrawal symptoms upon cessation of their drug use. Short-term residential 
treatment can also be used to commence opioid maintenance treatment.  
Any person likely to experience a severe withdrawal syndrome following cessation of drug 
use, and people for whom their current drug use is causing a significant risk of harm are 
most in need.  
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The following criteria should be considered when deciding whether a short-term residential 
treatment or another treatment setting is applicable: 
• Type of drug being used, 
• Likelihood of withdrawal syndrome, 
• Severity of drug dependence, 
• Related health and social problems, 
• Co-occurring medical and psychiatric problems, 
• Sedative and opioid withdrawal can be severe, and is highly likely for people using 
high doses over extended periods of time.  
 
 
3.3.4 Treatment models and methods used 
 
Achieving the therapeutic goals of short-term residential treatment typically requires a 
combination of interventions such as psycho-education on drug-effects, motivational 
counseling, pharmacotherapy and support through drug withdrawal. Other interventions  
which can be initiated are introduction to behavioral therapy, orientation to self-help groups, 
social services, and appropriate referrals for follow-up care after discharge. The specific 
types and the duration of these interventions differ depending upon the nature, complexity 





Short-term residential treatment programmes for drug use disorders should include the 
following activities:  
• Comprehensive medical and psychosocial assessment 
• Treatment plan which best addresses individual needs 
• Medication-assisted detoxification if indicated 
• Initiation of maintenance medication if indicated 
• Strategy to foster patients’ motivation for change 
• Contact with individuals that are of significance in patient’s social network to engage 
them in the treatment plan 
• Initiation of behavioral treatment strategies for the treatment of drug use disorders 
• Initiation of treatment for co-occurring medical and psychiatric disorders, if time and 
resources permit 
• Ongoing evaluation of patient’s progress in treatment, and continuous clinical 
assessment that is built into the programme 
• Discharge planning with relapse prevention and continuing care strategies for the 
period after residential treatment, including maintenance medication if indicated, an 
appropriate level of psychosocial treatment, and ongoing treatment for co-occurring 
medical and psychiatric problems.  
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Either prior to admission, preferably, or on admission to short-term residential treatment a 
comprehensive medical and psychosocial evaluation of every patient should be conducted 
to determine the unique needs and the treatment plan for each patient. This should include 
medical and psychiatric history, and both physical and mental status examinations. It may 
also be valuable to conduct some laboratory investigations, including urine drug screen, and 
testing for HIV and hepatitis.  
 
An evidence-based assessment tool such as the Addiction Severity Index (ASI), which 
evaluates severity of drug use problems and associated problems (medical, psychiatric, 
family, etc.) can be administered by a trained staff member. When the patient is not in acute 
withdrawal, a structured interview for psychiatric disorders such as the MINI, SCID, or CIDI-
SAM may be considered and are particularly useful for both establishing drug use disorders 
and identifying co-occurring psychiatric disorders.  
 
Immediately after admission to short-term residential treatment, patients should be 
monitored multiple times per day regarding withdrawal symptoms, and any acute medical or 
psychiatric problems. Once these acute problems have stabilized, daily monitoring should 
focus on both medical and psychiatric status, as well as the motivation and development of 
goals and plans for treatment after discharge. 
 
 
3.3.5 Treatment of withdrawal  
 
The treatment of withdrawal, also called detoxification, is typically the foremost concern if a 
patient has had a protracted, and severe recent history of opioid, alcohol, benzodiazepine 
or barbiturate use. In these cases, there are established withdrawal protocols usually 
employing pharmacotherapy combined with rest, nutrition and motivational counseling. 
Unrecognized and untreated withdrawal is likely to drive a patient out of treatment. Thus, 
staff of short-term residential treatment programmes need to be knowledgeable about the 
various withdrawal syndromes, and be prepared to be psychologically supportive, motivating 
the patient to get through the withdrawal phase, and able to prescribe effective medication 
treatments for withdrawal. 
 
Short-term residential treatment services need to be either capable of the medical 
management of the severe symptoms of withdrawal syndrome, or have the ability to transfer 
such patients to a medical hospital. 
 
Opioid withdrawal syndrome 
Pharmacological treatment of opioid withdrawal includes either short-term treatment with 
methadone and buprenorphine, or alpha-2 adrenergic agonists (clonidine or lofexidine). If 
neither of these are available, reducing doses of weak opioids can be used, as well as 
medications to treat the specific symptoms that arise (sedatives for anxiety and insomnia, 
analgesics for muscle pains, anti-diarrhoeals, and anti-emetics. Nevertheless, people with 
opioid dependence generally have better outcomes with long-term opioid agonist treatment, 
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as they are at increased risk of overdose following detoxification alone. If available, people 
with opioid dependence and their families should be given naloxone to take home in case 
of an opioid overdose, and trained in the management of opioid overdose. 
 
Sedative-hypnotic withdrawal syndrome 
Patients admitted to a short-term residential treatment programme should be asked about 
alcohol and sedative use, monitored for the emergence of withdrawal symptoms, or treated 
prophylactically if deemed high-risk (heavy or regular use, or history of past withdrawal 
episodes).   
 
Sedative-hypnotic withdrawal can be effectively treated with long-acting benzodiazepines 
starting at a dose sufficient to relieve withdrawal and tapering slowly over a period of days 
or weeks. Patients need to be monitored for the emergence of severe manifestations of 
alcohol or sedative-hypnotic withdrawal, including seizures, cardiovascular instability and 
delirium. It should be ensured that the treatment is not simply prolonging sedative-hypnotic 
use.   
 
Stimulant withdrawal syndrome 
Stimulant withdrawal (the ''crash") is less well defined than syndromes of withdrawal from 
central nervous system depressant substances; depression is prominent and is 
accompanied by malaise, inertia, and instability. 
 
Cannabis withdrawal syndrome 
A cannabis withdrawal syndrome can occur in heavy users, typified by insomnia, 
headaches, depressed mood and irritability.  
 
Pharmacological treatment of stimulant and cannabis withdrawal depends on symptom 
emergence.  
 
3.3.6 Treatment of co-occurring psychiatric and medical problems 
 
Psychiatric disorders, including depression, anxiety, post-traumatic stress disorder,  
schizophrenia or other psychotic disorders, are associated with drug use disorders and may 
interfere with engagement in treatment. Psychiatric symptoms, including depression, 
anxiety, and psychosis, may be caused or exacerbated by the use of different drugs and 
may resolve when drug use is stopped.   
 
A critical first step in the accurate evaluation of psychiatric symptoms among drug users is 
to distinguish independent disorders from disorders that are substance-induced and will 
resolve with abstinence. 
 
Short-term residential treatment can provide an opportunity to observe whether psychiatric 
symptoms are resolved when abstinence from substances is achieved, and to initiate 
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medical or psychosocial treatment for disorders that persist after cessation of substance 
use.   
 
A comprehensive assessment of the patient should be administered on entry into any 
treatment programme that is as comprehensive as possible and includes a medical history, 
presence of chronic and acute diseases and related pharmaceutical therapies, as well as a 
routine documentation of infectious diseases including HIV, Tuberculosis, Hepatitis etc. 
 
Any acute medical conditions seen on admission may need to be managed prior to any 
further treatment or care. These can include: confusion, excessive sedation, hallucinations, 
seizures or fever. Depending on local conditions, mechanisms for treating opioid 
dependence should be combined, if necessary, with treatment for TB, HIV and hepatitis, to 
ensure continuity of anti-infective agents. A short-term residential treatment programme may 
not have medical expertise, or the time to initiate such treatment, but consultation and 
referral to appropriate services should be available.  
  
Hepatitis B is common in many drug use populations, particularly (but not exclusively) to 
those who inject drugs. Short-term residential treatment can be an opportunity to vaccinate 
against hepatitis B. Depending on the length of the treatment, an accelerated vaccination 
schedule, consisting of 2 or 3 doses, may be administered to people who have not had a 
complete course of hepatitis B vaccination before, and without necessarily testing serology 
beforehand (WHO, 2012).  
 
Chronic pain is another common problem which may contribute to the motivation to use illicit 
drugs, particularly opioids, and to the risk of relapse. Referral for further evaluation of the 
source of the pain and specific management strategies should be arranged. 
 
3.3.7  Follow-up treatment  
 
Entry and engagement with short-term residential treatment is often an important first step 
in treating drug-use disorders. Nevertheless maintenance of sustainable healthy behaviours 
are of particular importance after patients leave treatment as the risk of relapse and 
overdose increases significantly immediately after discharge. 
 
An effective follow-up treatment plan should include strategies for patients to successfully 
transition to the next level of care and maximize the chances to maintain medical and 
psychological health. Health and social care professionals should work together to provide 
patients with the necessary resources and consider the following treatment dimension when 
planning a discharge from residential to outpatient treatment or to a long-term residential 
programme: 
 
Availability of social supports  
Social networks are influential to patterns of drug consumption and good social support can 
help patients to recover and maintain abstinence. Patients should be educated and made 
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aware of the different factors that contribute to their harmful drug use and equipped with 
different strategies to create and maintain an environment that promotes health.  
 
Long-term medication treatment   
For opioid dependence, treatment plans usually include long term maintenance on 
medication (methadone maintenance, buprenorphine maintenance, or extended-release 
naltrexone). Opioid agonists (methadone and buprenorphine) reduce drug use, crime and 
the risk of dying from opioid dependence by approximately two thirds. The opioid antagonist 
naltrexone has been shown to be more effective than placebo. Ideally, medication should 
be started during in-patient treatment  and continued after discharge at an outpatient 
medication maintenance programme.  
 
Follow-up care 
Psychosocial care for substance use disorders needs to continue after short-term residential 
treatment. For patients with more severe substance use disorders and the lack of social 
support, referral to long term residential treatment is indicated after short-term residential 
treatment. For patients with lower severity and better social supports, outpatient treatment 
can be an advisable next treatment modality. Support to navigate the social care system 
should be present to access vocational training, stable housing, etc. as needed. 
 
3.3.8 Criteria for programme completion and indicators of effectiveness 
 
Successful completion of short-term residential treatment can be evaluated for each patient 
on the basis of several dimensions including:  
• Resolution of withdrawal symptoms 
• Understanding of the substance use disorder and related problems 
• Motivation to engage in follow-up treatment after discharge in either long-term 
residential treatment or outpatient treatment 
• Improvement in physical and mental health, and initiation of treatment and/or 
discharge plans to handle such problems over the long term 
• Improvement in craving for drugs and beginning development of skills to control over 
triggers (thoughts, emotions, and behaviors) that lead to drug use 
 
The effectiveness of a short-term residential treatment programme can be evaluated by 
process indicators (i.e. what services are delivered or what goals are met by patients during 
the treatment stay), or objective measures of patients’ long term outcome after discharge. 
One objective outcome measure would be the proportion of patients who engage in follow-
up treatment after discharge. Another outcome indicator would be abstinence and other 
markers of recovery at long-term (e.g. 6-month) follow-up. This type of long-term indicator 
is rarely implemented in routine care, as it requires tracking and long term follow-up of 
patients.    
 
3.3.9 Rating the strength of evidence 
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• There is evidence from Randomized Clinical Trials (RCTs) that methadone, 
buprenorphine, clonidine and lofexidine are effective in supporting detoxification from 
opioid dependence.  
• There is evidence from a small number of RCTs indicating that long term agonist 
treatments are more effective than detoxification for opioid dependence.  
• There is evidence from RCTs that psychosocial support improves the outcomes of 
detoxification in opioid dependence.  
• There is one RCT which compared inpatient to outpatient detoxification for opioid 






• The treatments provided are regularly reviewed and modified by staff in conjunction 
with the patient to ensure appropriate management 
• Clearly defined protocols exist for prescribing medications and other interventions 
appropriate to the specific needs of patients 
• The protocols are firmly based on research findings wherever possible. If that is not 
possible, they are in line with recognized good clinical practice 
• The range of relevant treatment options available is described to the patient 
• On-site or off-site laboratory and other diagnostic facilities are available  
• Access to self-help and other support groups is available 
• Whether or not the goal of treatment is abstinence, measures are taken to reduce the 
harm of continued drug use (health diet, use of sterile injection equipment) 
• When a procedure with known risks is under consideration a careful risk/benefit 
evaluation is carried out resulting in selection of the least risk producing criteria 
• A mechanism exists to ensure continuity of patient care 
• There is a regular assessment of the effectiveness of the services (i.e., programme 
evaluation) 
• Links exist between the dependence treatment programmes and other services 
which facilitate interventions with children and other family members of patients who 
have suffered psychologically or socially 
• Emergency support or transport in case of life threatening complications of drug use 
or withdrawal is available 
• There are defined criteria for the expulsion of patients due to violation of treatment 
service rules, violence, continued non-prescribed drug use, etc. 
• There are defined criteria for the management of specific risk situations (e.g., 




                                            
3 WHO 
http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf 




• The provider has a system laid out that ensures that the method for selecting, hiring 
and training staff corresponds to valid legal norms and established internal rules. 
• The organisation has rules defined that the staff follows in cases where valid 
legislation is too general. 
• The structure and management of the organisation is defined, making competences 
for individual positions clear. 
• The provider has specified the structure and staffing needs, as well as corresponding 
job profiles and staff qualifications, taking into account the needs and current number 
of service users for service organisation. The composition and additions to the team 
correspond to these needs. 
• Prevention of work risks has been secured. 
• Cases where a patient’s rights have been violated by an employee and the 
corresponding measures that were taken are documented in personnel records. 
• Specialised care (medical, psychological, psychotherapeutic, social, educational 
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3.4 Outpatient Treatment 
 
3.4.1 Brief Definition and Description of the Setting 
 
The outpatient treatment setting for the treatment of substance use disorders cares for 
people who do not reside in the treatment facility, who live at home instead and visit the 
treatment facility only for treatment interventions. Outpatient services vary considerably in 
terms of their components and intensity. Typically outpatient drug treatment is either carried 
out by health and social services specializing in the treatment of substance use disorders, 
or within the context of mental health treatment more broadly.  
 
The range of treatment offered in the outpatient setting include: 
- psychological interventions 
- social support 
- pharmacological interventions  
 
3.4.2 Target Population 
 
Outpatient treatment in its different modalities can cater for a broad range of individuals, but 
some modalities such as psychological therapies are more appropriate for individuals who 
have sufficient social support and resources at home and in their communities, and who are 
able to be sober enough to benefit from such treatment.   
 
3.4.3 Goals  
 
The primary goals of outpatient treatment are to help patients to stop or reduce drug use; to 
minimize medical, psychiatric and social problems associated with drug use; to reduce the 
risks of relapse and to improve their well-being and social functioning, as part of a long-term 




Outpatient treatment services and programmes vary considerably depending on the 
services’ level of intensity and interventions they offer.  
 
High-Intensity Interventions 
Programmes such as intensive day treatment require frequent interactions with patients (i.e. 
daily, or several hours on one or more days). Components and activities of these service 
settings include: 
• Comprehensive medical and psychosocial assessment on admission 
• Treatment plan which best addresses individual needs 
• Treatment is voluntary, with patient participation in treatment decisions 
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• Medication-assisted detoxification, if indicated 
• Initiation of maintenance medication if indicated 
• Contact with family and significant others of the social network to engage them in the 
ongoing treatment 
• Behavioral and psychosocial treatment for substance use disorder and co-occurring 
psychiatric disorders 
• Pharmacological treatment for co-occurring medical and psychiatric disorders 
• Treatment contract which clearly outlines all treatment procedures, services and 
other policies and regulations as well as programme’s expectations of the patient 
• Ongoing evaluation of patient’s progress in treatment, and continuous clinical 
assessment that is built into the programme  
• Relapse prevention and discharge strategies for continuous care after residential 
treatment, including maintenance medication if indicated, an appropriate level of 
psychosocial treatment, and ongoing treatment for co-occurring medical and 
psychiatric problems 
• Intensive social support including accommodation and employment   
 
Mid to Low-Intensity Interventions 
Lower intensity interventions involve weekly group support sessions, individual 
psychological treatment, health and drug education, and lower intensity social support. 
 
In the course of outpatient treatment, associated health care professionals may regularly 
assess drug and alcohol use, and physical and mental health status of patients. Routine 
cooperation with allied care services is essential and should include integration of outpatient 
treatment with medical services for HIV, viral hepatitis, TB and sexually transmitted 
infections.  
 
Routine cooperation with social support and other agencies, including education, 
employment, welfare, support sources for disabled, housing, social networking or legal 
assistance should also be present.   
 
3.4.5 Models and Methods 
 
Treatment objectives can be best accomplished by using a combination of pharmacological 
and psychosocial interventions. Ideally, outpatient treatment programmes for drug use 
disorders offer a comprehensive range of services to manage various problems affecting 
patients across several life domains.   
 
3.4.6 Evidence-based  psychosocial and behavioral interventions 
 
Psychosocial interventions should be used in outpatient treatment programmes to address 
motivational, behavioral, psychological, social, and environmental factors related to 
substance use and have been shown to reduce drug use, promote abstinence and prevent 
relapse. Psychosocial interventions can also be used to increase adherence to treatment 
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and medications. For different drug use disorders, the evidence from clinical trials supports 
the effectiveness of cognitive behavioral therapy (CBT), motivational interviewing (MI), 
community reinforcement approach (CRA), motivational enhancement therapy (MET), 
family therapy (FT) modalities, contingency management (CM), insight oriented treatments, 
12-step group facilitation, housing and employment support among others. 
 
Cognitive Behavioral Therapy (CBT) 
CBT is based on the understanding that behavioral patterns and cognitive processes around 
drug use are learned and can be modified. During treatment patients are introduced to new 
coping skills and cognitive strategies to replace the maladaptive behavioral and thinking 
patterns. CBT therapy sessions are structured with specific goals to be accomplished at 
each session and focused on immediate problems faced by the drug user. CBT can be used 
as a short-term approach that can be adapted to a wide range of patients and a variety of 
settings and both individual and group treatment sessions. CBT can be combined with a 
range of other psychosocial and pharmacological treatments. 
 
Contingency management (CM) 
CM involves giving patients concrete non-monetary rewards to reinforce positive behaviors 
such as abstinence, treatment attendance, compliance with medication, or their own 
particular treatment goals. An objective measure of an agreed positive outcome (typically 
supervised urine collection and toxicology testing) with immediate feedback are necessary 
for CM effectiveness. Test results provide an indicator of treatment progress and these may 
be discussed in confidential therapy sessions to promote better understanding of the patient 
condition. A CM approach is often used as a part of treatment that focuses on promoting 
new behaviors that are competing with drug use and can be combined with CBT.  
 
Patients treated with CM often show greater initial reductions in drug use than in other 
treatments, although there are questions about the persistency of these effects unless CM 
is combined with other treatment approaches. CM has been found to be particularly useful 
in treatment of patients with amphetamine and cocaine use disorder helping to reduce 
treatment dropout and to decrease drug use. Other studies found that CM using vouchers 
for the reward of high performance in the treatment were effective in increasing the level of 
employment for drug users in treatment. Although many of the research trials use monetary 
reinforcement, the use of contingency management should be adapted to the culture and 
population with input from patients. 
 
Motivational Interviewing (MI) and Motivational Enhancement Therapy (MET) 
Motivational Interviewing is collaborative, evocative, and recognizes the autonomy of the 
patient. The clinician assumes an advisory, rather than an authoritative role, and seeks to 
understand what the patient values – this process builds empathy and fosters a therapeutic 
alliance from which it may be possible to promote behavioral modifications. In this process 
the patient may realize that their drug use behavior is inconsistent with the things that are 
important to them. MI is also promising as an approach to reduce high-risk behaviors such 
as unprotected sex and sharing needles. MI can be delivered in one or two sessions for less 
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severe forms of drug use, or the approach can be extended (where it is called MET) over 6 
or more sessions for more severe drug use disorders. 
 
Involvement of family members and concerned significant others   
Family-oriented treatment approaches have been found effective to improve engagement 
with treatment, reduce drug use, and improve participation in aftercare when compared to 
care focused on the individual patient. Family-oriented approaches are particularly useful in 
educating patients and their families about the nature of drug use disorders and the process 
of recovery. 
 
Effective family-oriented approaches identified include: Behavioral Couples Therapy, Brief 
Strategic Family Therapy, Multisystemic Therapy and Multidimensional Family Therapy 
(MDFT).    
 
MDFT appears to be particularly effective in treating cannabis dependence in adolescence. 
Couples therapy has been examined more in the context of alcohol dependence treatment, 
but may also play a role in drug dependence treatment.   
 
Working with the family can also be helpful when the patient refuses to be involved in 
treatment using approaches such as Unilateral Family Therapy or Community 
Reinforcement and Family Training.   
 
WHO Recommendations: 
Psychosocial interventions including contingency management, and cognitive behavioural therapy (CBT) 
and family therapy can be offered for the treatment of psychostimulant dependence.  
Psychosocial interventions based on cognitive behavioural therapy or motivational enhancement therapy 
(MET) or family therapy can be offered for the management of cannabis dependence. 
Behavioural interventions for children and adolescents, and caregiver skills training, may be offered for 
the treatment of behavioural disorders. 
Psychosocial interventions including cognitive behavioural therapy (CBT), couples therapy, 
psychodynamic therapy, behavioural therapies, social network therapy, contingency management and 




3.4.7 Evidence-based pharmacological interventions 
 
Medications can be very helpful in managing/treating a variety of drug use disorder aspects 
such as intoxication, overdose, withdrawal, dependence and psychiatric problems related 
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3.4.8 Pharmacological Treatment 
 
3.4.8.1 Pharmacological Treatment of Opioid Use Disorders 
Opioid Overdose  
Opioid overdose can be identified by a combination of three symptoms: 1) pinpoint pupils, 
2) unconsciousness, and 3) respiratory depression. The opioid antagonist naloxone can 
completely reverse the effects of opioid overdose within minutes and is a lifesaving 
treatment. With a long history of clinical success and extremely rare adverse effects, 
Naloxone should therefore be available in all health-care facilities that may be called upon 
to respond to opioid overdose.  
 
Naloxone can be injected intramuscularly, subcutaneously, intravenously, or can also be 
administered intranasally. Improvised intranasal devices made by adding an atomiser to a 
syringe containing naloxone have been shown to be effective in clinical trials, although 
sometimes a second dose was needed. Commercial intranasal formulations are more 
concentrated than those for injection, as the nasal mucosa has a limit to the amount of liquid 
it can absorb at one time. The doses used for intranasal administration may need to be 
higher than that used intramuscularly. 
 
In addition to the administration of naloxone, the treatment of opioid overdose includes 
attempting to rouse the person, to call an ambulance, resuscitation techniques such as 
rescue breathing, and to stay with the person until they are fully recovered. 
 
Naloxone and resuscitation training should be distributed to patients, family members and 
other people likely to witness an opioid overdose.  
 
WHO Recommendations (2014) 
Naloxone should be available in all health-care facilities that may be called upon to respond to opioid 
overdose. 
Use of a range of treatment options for opioid dependence include psychosocial support, opioid 
maintenance treatments such as methadone and buprenorphine, supported detoxification and treatment 
with opioid antagonists such as naltrexone.  
Naloxone should be made available to people likely to witness an opioid overdose, as well as training in 
the management of opioid overdose. 
 
Opioid Detoxification 
The main goal of detoxification is to stabilise a patient’s physical and psychological health 
while managing the symptoms of withdrawal on cessation or reduction of drug use. 
Detoxification is necessary before starting subsequent treatment, however, this is a 
particularly vulnerable time for patients as recent periods of abstinence are major risk factors 
for fatal opioid overdose due to a reduction in tolerance and inaccurate judgment with 
respect to dosage. Where available, reducing daily supervised doses of methadone and 
buprenorphine over 1-2 weeks can be used safely and effectively for opioid detoxification. 
Otherwise, low doses of clonidine or lofexidine, or a gradual reduction of weaker opioid 
medications can be used to, along with specific medications, treat the symptoms of opioid 
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withdrawal as they emerge (i.e anti-emetics, anti-diarrhoeals, analgaesics, sedatives). 
Clinicians should only prescribe sedating medications for short periods and closely monitor 
treatment response as the risk of tolerance and medication misuse may develop for some 
medications with longer use. The effectiveness of treatment is greater when psychosocial 
assistance is made available during withdrawal management. 
  
WHO Recommendations 
Standard Recommendations Strong Recommendations 
For the management of opioid withdrawal, tapered 
doses of opioid agonists (methadone or 
buprenorphine) should preferably be used, 
although alpha-2 adrenergic agonists may also be 
used.  
 
Clinicians should not use the combination of 
opioid antagonists with heavy sedation in the 
management of opioid withdrawal. 
Clinicians should not routinely use the 
combination of opioid antagonists and minimal 
sedation in the management of opioid withdrawal.  
 
Psychosocial services should be routinely offered 




Opioid Dependence  
Opioid dependence generally has a chronic and relapsing course and therefore a long-term 
relapse-prevention treatment should be implemented for individuals who stop the use of 
opioids. Relapse-prevention treatment should include a combination of pharmacological 
treatment and psychosocial intervention. The outcome of treatment that includes only 
psychosocial approaches is inferior to treatment that also includes appropriate medication. 
 
The two main pharmacological therapeutic strategies to address opioid dependence are:  
1. Opioid Agonist Maintenance Treatment (OAMT) with long acting opioids (methadone 
or buprenorphine). 
2. Detoxification followed by relapse-prevention treatment using opioid antagonist 
(naltrexone).  
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Opioid Agonist Maintenance Treatment (OAMT) 
WHO Opioid agonist maintenance treatment recommendations. 
Standard Recommendations Strong Recommendations 
Average buprenorphine maintenance doses should 
be at least 8 mg per day. 
For opioid agonist maintenance treatment, most 
patients should be advised to use methadone in 
adequate doses in preference to buprenorphine.  
Take-away doses may be provided for patients when 
the benefits of reduced frequency of attendance are 
considered to outweigh the risk of diversion, subject 
to regular review.  
During methadone induction, the initial daily dose 
should depend on the level of neuroadaptation; it 
should generally not be more than 20 mg, and 
certainly not more than 30mg.  
  
On average, methadone maintenance doses 
should be in the range of 60–120 mg per day.  
  
Methadone and buprenorphine doses should be 
directly supervised in the early phase of 
treatment. 
  
Psychosocial support should be offered routinely 
in association with pharmacological treatment for 
opioid dependence. 
 
The primary aim of Opioid Agonist Maintenance Treatment (OAMT) is to reduce the use of 
illicit opioids and manage abstinence by preventing withdrawal symptoms, reducing drug 
craving, and decreasing effects of additional opioids if they are consumed.  
 
Methadone Maintenance Treatment 
Compared to treatment without medication, methadone-treated patients show marked 
reductions in heroin and other drug use, have lower mortality, fewer medical complications, 
lower rates of HIV and hepatitis transmission, decreased criminal activity, and have 
improved social and occupational functioning.  
 
Methadone should be commenced following the general rule ‘start low, go slow’. The initial 
dose should generally be 20mg or less, depending on the level of opioid tolerance, allowing 
a high margin of safety to minimize the risk of methadone overdose. Small additional doses 
can be given, if necessary, up to 30mg. Once inducted safely, the goal is to achieve an 
optimal dose for longer-term maintenance to prevent craving and the use of illicit opioids. 
The initial dose should be gradually adjusted upwards to reach the optimal dose which 
eliminates opioid cravings while producing neither sedation nor euphoria and allows patients 
optimal functioning in all areas of their life. The dose should be adjusted upwards if there is 
ongoing heroin use and downwards if there is any sedation, or if the person is ready to cease 
treatment.  
 
Typically, effective methadone maintenance doses range from 60 to 120mg/day and depend 
on individual factors such as the ability to metabolize medication and metabolic 
interferences by other medications that can change the blood level of methadone (i.e. HIV 
or TB medications, psychiatric, or cardiac medications). 
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In order to maintain adequate plasma levels and avoid opioid withdrawal it is important that 
methadone is administered daily and that patients are regularly monitored for adherence to 
the medication regime. At the start of treatment methadone should be administered under 
supervision. Once the patient is stabilized, take home doses can be introduced according 
to local laws and an individual risk-benefit assessment. 
 
As methadone is an opioid, some people may try to illicitly sell their prescribed methadone. 
This can be reduced, among other measures,  by diluting the supervised dose  and by 
diluting the take home dose of methadone to a point where it is less likely to be injectable.  
 
 
Buprenorphine and buprenorphine/naloxone combination  
Aims and principles of buprenorphine maintenance treatment are similar to those of 
methadone maintenance treatment: prevent craving and the use of illicit opioids. When 
initiating treatment with buprenorphine, the first dose should be administered with a range 
of 2-4mg at least 8-12 hours after the last use of opioid or when symptoms of opioid 
withdrawal occur. In contrast with the premise for methadone induction (‘start low, go slow’), 
buprenorphine induction should proceed rapidly once the first dose has been shown to be 
well tolerated as the risk of toxicity is low due its partial agonist action. 
 
Effective maintenance doses for buprenorphine range from 8 to 24 mg per day not 
surpassing a maximum daily dose of 32mg. Alternate-day dosing, using double the daily 
dose, may be considered in patients who require supervised dosing and do not require an 
alternate daily dose of more than 32mg. Compared to methadone, buprenorphine interacts 
less with other commonly administered medications. As with methadone, it is recommended 
that buprenorphine doses should be administered under supervision until the patient is 
WHO Recommendations for use of methadone in maintenance treatment 
Pharmacological treatment options should consist of both methadone and buprenorphine for opioid 
agonist maintenance and opioid withdrawal, alpha-2 adrenergic agonists for opioid withdrawal, naltrexone 
for relapse prevention, and naloxone for the treatment of overdose. 
The initial methadone dose should be 20mg or less, depending on the level of opioid tolerance, allowing a 
high margin of safety to reduce inadvertent overdose.  
The dosage should be then quickly adjusted upwards if there are ongoing opioid withdrawal symptoms 
and downwards if there is any sedation.  
A gradual increase to the point where illicit opioid use ceases; this is likely to be in the range of 60–120 
mg methadone per day. 
Patients should be monitored with clinical assessment and drug testing.  
Psychosocial assistance should be offered to all patients. 
Methadone use should be supervised initially. 
The degree of supervision should be individually tailored, and in accordance with local regulations; it 
should balance the benefits of reduced dosing frequency in stable patients with the risks of injection and 
diversion of methadone to the illicit drug market. 
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stable and then take home doses can be introduced according to local laws and an individual 
risk-benefit assessment. 
 
To reduce the attractiveness of people injecting or selling the buprenorphine tablets, 
buprenorphine also exists in a buprenorphine-naloxone combination. This combination 
makes it less attractive to opioid users and they may experience withdrawal symptoms if 
they inject it. Since the sublingual formulation can take up to 15 minutes to fully dissolve in 
the mouth, a film formulation has also been developed which solidifies in contact with water 
and makes injecting much more difficult.  
 
 
Opioid antagonist treatment with naltrexone 
Treatment with the long acting opioid antagonist naltrexone can only be initiated following 
detoxification in individuals who have not used opioids for one week or more (e.g., typically 
those leaving residential treatment). Naltrexone is used to prevent relapse; it blocks the 
effects of opioids for 1-2 days. Unless the patients are sufficiently well motivated, the rates 
of treatment drop out can be high.  
 
Naltrexone can be useful to patients who:  
1) do not have access to treatment with agonists,  
2) have high motivation for abstinence from all opioids,  
3) are unable to take agonist treatment due to adverse effects, or  
4) have been successful on agonist treatment but want to discontinue agonists 
treatment and be additionally protected against relapse.  
 
Naltrexone is available as an oral tablet which can be taken daily (50 mg/day) or three times 
a week (100-150 mg each dose) to maintain blocking blood levels of the medication. 
Naltrexone is also available in extended-release depot injection preparation (given as 
injection or as an implant) that can maintain blocking levels of the medication for 3-6 weeks 
after a single dose. A number of naltrexone implant formulations are in circulation which 
report even longer duration of opioid blocking.  
 
  
When managing people who are dependent on strong prescription opioids (i.e. morphine-like), physicians 
can switch to a long acting opioid (such as methadone and buprenorphine) which can be taken once 
daily, with supervised dispensing if necessary, either for maintenance treatment or for detoxification.  
 
WHO, 2009 
WHO Recommendation for Opioid Antagonist treatment with naltrexone. 
 
For opioid-dependent patients not commencing opioid agonist maintenance treatment, antagonist 
pharmacotherapy using naltrexone should be considered following the completion of opioid withdrawal. 
WHO, 2009 
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3.4.8.2 Pharmacological Treatment of Psychostimulant Use Disorders  
Psychostimulants such as amphetamines and cocaine are one of the most frequently used 
and problematic illicit substances in many parts of the world. To date there is no medication 
proved consistently efficacious for the treatment of psychostimulant use disorders. At 
present, medications are primarily used to manage co-occurring psychiatric disorders and 
withdrawal symptoms.  
 
If a stimulant withdrawal syndrome is observed, symptomatic medications can be used to 
treat withdrawal symptoms as required (i.e. anti-emetics, anti-diarrhoeals, analgesics, 
sedatives). However clinicians should prescribe these medications for short periods of time 
only and closely monitor the treatment response as the risk of tolerance and medication 
misuse may develop with a longer use. 
 
Antipsychotic and sedative medications may be used to manage psychotic symptoms 
resulting from acute psychostimulant intoxication. As more than half of the patients with a 
psychostimulant use disorder have a co-occurring major psychiatric disorder, (e.g. major 
depressive disorder, bipolar disorder, or schizophrenia), appropriate psychotropic 
medications play a major role in the treatment of psychostimulant use disorders. Frequently 
patients with a psychostimulant use disorder also have another substance use disorder, 
(e.g. alcohol or opioid dependence) which should be treated using pharmacological as well 
as psychosocial approaches.  
  
 
Pharmacological Treatment of Cannabis Use Disorders  
To date there is no approved pharmacological treatment of cannabis use disorders and 
psychosocial treatment remains the primary approach.  If a cannabis withdrawal syndrome 
is observed, symptomatic medications can be used to treat withdrawal symptoms as 
required (i.e. anti-emetics, anti-diarrhoeals, analgaesics, sedatives), however clinicians 
should prescribe these medications for short periods of time only and closely monitor the 
treatment response as the risk of tolerance and medication misuse may develop with a 
longer use. 
 
Pharmacotherapy of comorbid mental disorders 
Many patients with drug use disorders also experience comorbid mental disorders such as 
depression, post-traumatic stress disorder, mania or psychosis. 
Soon after cessation of drug use many patients experience psychiatric symptoms such as 
anxiety or insomnia which may be treated with symptomatic medications. However, 
sedative-hypnotic medications such as benzodiazepines should be used with caution as a 
first line of treatment as they have a high dependence potential. Rather, alternative 
WHO Recommendation for treatment of psychostimulant dependence 
Dexamphetamine should not be offered for the treatment of stimulant use disorders in non-specialized 
settings. 
mhGAP, 2012 
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medications such as sedating antidepressants or low-dose neuroleptics should be 
considered in addition to psychosocial and behavioral treatment. 
 
3.4.9 Recovery Management and Social Support 
 
Recovery management combines a variety of activities that promote and strengthen internal 
and external resources to help patients manage voluntarily and actively drug-related 
problems and their recurrence. Some of these activities may be already present in the 
context of a patient’s home, neighborhood and community while others need to be 
developed. The following factors and activities increase social reintegration and improve 
chances of stable remission and recovery from substance use disorders:  
• Strengthening individual’s resilience, self-efficacy and self-confidence to manage 
daily challenges and stress while maintaining commitment to recovery and avoiding 
relapse to substance use  
• A supportive social network (i.e. partner, family members and friends) that can 
monitor the stability of recovery, abstinence from drugs and compliance with 
treatment 
• Stable accommodation 
• Meaningful work with appreciation in the work-place that replaces stigma and 
discrimination  
• Engagement with individuals and social networks of friends and workmates that have 
abstinence-oriented norms and are supportive of recovery goals  
• Political, humanitarian or spiritual involvement that provides a way to attribute 
meaning to life’s stressors and develop a stronger purpose in life  
• Social participation and integration in educational and vocational pursuits, including 
volunteering or community involvement  
• Remediation of legal and financial problems  
• Active involvement in self-help, religious or other support groups 
 
 
3.4.10 Rating of the strength of evidence  
 
• There is a large number of Randomized Clinical Trials (RCTs) comparing different 
approaches to psychosocial support, however most are underpowered to 
demonstrate a difference. A small number of trials shows that some approaches are 
better than waitlist, that some approaches are better than some other approaches, 
and that some approaches are equivalent to other approaches which have shown to 
be effective (see WHO mhGAP review for details).  
• There is evidence from RCTs that psychosocial support combined with Opioid 
Agonist Maintenance Treatment (OAMT) is better than OAMT alone4.  
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• There is strong evidence from RCTs on the benefits of methadone and 
buprenorphine maintenance, and of the effectiveness of methadone and 
buprenorphine for detoxification5.  
• There is weak evidence for the benefits of oral naltrexone for opioid dependence6.  
 
 
3.4.11 Recommendations for outpatient treatment services 
 
Information about 24-hour emergency facilities is provided to patients and their relatives who 
are being treated on an outpatient basis. 
Outpatient Opioid Disorder Management 
• Opioid withdrawal services should integrate treatment of withdrawal with other 
ongoing treatment options. 
• Essential pharmacological treatment options should consist of opioid agonist 
maintenance treatment and services for the management of opioid withdrawal. At a 
minimum, this would include either methadone or buprenorphine for opioid agonist 
maintenance and outpatient withdrawal management. 
• Pharmacological treatment options should consist of both methadone and 
buprenorphine for opioid agonist maintenance and opioid withdrawal, alpha-2 
adrenergic agonists for opioid withdrawal, naltrexone for relapse prevention, and 
naloxone for the treatment of overdose. 
• Take-home doses can be recommended when the dose and social situation are 
stable, and when there is a low risk of diversion for illegitimate purposes. 
• Involuntary discharge from treatment is justified to ensure the safety of staff and other 
patients, but noncompliance with the programme rules alone should not generally be 
a reason for involuntary discharge. Before involuntary discharge, reasonable 
measures to improve the situation should have been taken, including re-evaluation 
of the treatment approach used. 
• Laboratory or other facilities are available for the monitoring of progress and 
compliance with the treatment being administered. 
• There are defined criteria for the management of specific risk situations (e.g., 
intoxication, suicide risk). 
 
Assessment and Choice of Treatment 
• The choice of treatment for an individual should be based on a detailed assessment 
of the treatment needs, the appropriateness of treatment to meet those needs 
(assessment of appropriateness should be evidence based), the patient acceptance 
and the treatment availability. 
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• Voluntary testing for HIV and common infectious diseases should be available as part 
of an individual assessment, accompanied by counselling before and after testing. 
• Ideally, all patients should be tested at initial assessment for recent drug use. 
• Treatment plans should take a long-term perspective. 
• Opioid withdrawal should be planned in conjunction with ongoing treatment. 
Range of Services Offered 
• Pharmacological treatment options should consist of both methadone and 
buprenorphine for opioid agonist maintenance and opioid withdrawal, alpha-2 
adrenergic agonists for opioid withdrawal, naltrexone for relapse prevention, and 
naloxone for the treatment of overdose. 
• A variety of structured psychosocial interventions should be available, according to 
the needs of the patients. Such interventions may include - but are not limited to - 
different forms of counselling and psychotherapy, and assistance with social needs 
such as housing, employment, education, welfare and legal problems. 
• Onsite psychosocial and psychiatric treatment should be provided for patients with 
psychiatric comorbidities. 
Treatment for Comorbid Medical Conditions 
• Where there are significant numbers of opioid dependent patients with either HIV, 
hepatitis or TB, treatment of opioid dependence should be integrated with medical 
services for these conditions. 
• For patients with TB, hepatitis or HIV and opioid dependence, opioid agonists should 
be administered in conjunction with medical treatment; there is no need to wait for 
abstinence from opioids to commence either anti-TB medication, treatment for 
hepatitis or antiretroviral medication. 
• Treatment services should offer hepatitis B vaccination to all opioid-dependent 
patients. 
• There should be intermittent or ongoing evaluation of both the process and outcomes 




• The provider has a system laid out that ensures that the method for selecting, hiring 
and training staff corresponds to valid legal norms and established internal rules. 
• The organisation has rules defined that the staff follows in cases where valid 
legislation is too general. 
• The structure and management of the organisation is defined, making competences 
for individual positions clear. 
• The provider has specified the structure and staffing needs, as well as corresponding 
job profiles and staff qualifications, taking into account the needs and current number 
of service users for service organisation. The composition and additions to the team 
correspond to these needs. 
• Prevention of work risks has been secured. 
• Cases where a patient’s rights have been violated by an employee and the 
corresponding measures that were taken are documented in personnel records. 
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• Specialised care (medical, psychological, psychotherapeutic, social, educational 
etc.) is always carried out by personnel with relevant qualifications and licences. 
 
 
Discharge, Aftercare, and Referral  
 
• There are defined criteria for the expulsion of patients due to violation of treatment 
service rules, violence, continued non-prescribed drug use, etc. 
• Involuntary discharge from treatment is justified to ensure the safety of staff and other 
patients, but noncompliance with the programme rules alone should not generally be 
a reason for involuntary discharge. Before involuntary discharge, reasonable 
measures to improve the situation should have been taken, including re-evaluation 
of the treatment approach used. 
• There are defined criteria for the management of specific risk situations (e.g., 
intoxication, suicide risk). 
• Care plans are explored which map out alternative pathways which might be followed 
in the event of partial or complete failure of the original plan, or expulsion from drug 
treatment services. 
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3.5 Long-Term Residential Treatment 
 
 
3.5.1 Brief definition and description of the setting  
 
Residential treatment for drug use disorders exists in a variety of forms, having developed 
independently in a variety of settings. Residential treatment which intends to promote 
therapeutic change must be distinguished from supported accommodation that primarily 
functions as a housing intervention that is not providing active treatment.  
 
Long–term residential treatment can take place in a hospital environment, typically a 
psychiatric hospital, or in a therapeutic community (TC). A hybrid of therapy and community 
living, therapeutic communities have been developed from programmes of drug-free 
communal living with a mutual-support philosophy. Other models of long-term residential 
treatment have been developed to deal more specifically with co-occurring mental health 
disorders, and have characteristics of psychiatric and medical clinics with integrated 
psychotherapy, family therapy and pharmacological interventions.  
 
Staying long-term in a residential setting allows patients to be removed from the chaotic and 
stressful environment that might have contributed to their drug use. In a therapeutic 
environment that is free of drugs, and usually also free of alcohol, patients are no longer 
exposed to the usual cues that trigger drug seeking behavior and may find it easier to 
maintain abstinence and work towards recovery. 
 
Not every setting in which people with drug use disorders live together in an attempt to 
create a supportive environment for each other necessarily qualifies as a health care facility. 
However once a facility makes claims about providing health care benefits, once it accepts 
funding for therapeutic purposes, then by definition it is a health care facility, and as such, it 
would be expected to meet the standards of such health care facilities. The unique 
characteristic of the therapeutic community is that while it has the standards of a health care 
facility, it also maintains the less formal beneficial aspects of community living.  
 
TCs use the programme’s entire community, including other residents, staff, and the social 
context, as active components of the treatment. The environment is “drug free” meaning that 
residents agree not to bring or use drugs (including alcohol) while residing in the community.  
 
Although traditional models of long-term residential treatment include only psychosocial 
treatment methods, modern approaches may involve the use of medications to decrease 
drug cravings and manage comorbid psychiatric symptoms.  
 
The primary focus of treatment is on learning skills to control cravings and on developing 
new interpersonal skills, personal accountability, responsibility, and improving self-esteem. 
Long-term residential treatment programmes have rules and activities designed to help 
residents examine dysfunctional ways of thinking and behaving and assist them to adopt 
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new and more effective ways to interact with others. Comprehensive services including 
vocational skills, employment training, and treatment for mental health disorders may be 
provided in the residential setting. 
 
The intensive and supportive caregiving that patients experience in residential treatment 
represent an appropriate response to the personal history often characterized by poor 
parental care, emotional neglect, physical or sexual abuse, trauma, interpersonal violence 
and social exclusion. Additionally, the structured activities and the rules of the residential 
programme help patients develop better impulse control and delay gratification while 
learning skills to deal with frustration and to cope with stress. Taking on concrete 
commitments helps develop personal accountability and evaluate personal progress with 
measurable achievements.  
 
While the model of a therapeutic community is one of the oldest models of treatment of 
substance use disorders, and while it is well accepted in many countries, it is a model which 
has been difficult to test in clinical trials. The Cochrane review on Therapeutic Communities, 
for example, found evidence to support their efficacy only in the prison setting, and there is 
no specific WHO guidance on therapeutic communities. Without commenting on the 
effectiveness of the therapeutic community approach compared to other treatment 
modalities, this chapter will outline the standards expected of a long-term residential 
treatment, including therapeutic communities.  
 
3.5.2 Target population 
 
Patients who are unlikely to maintain abstinence outside of a structured environment to 
improve their life quality, or to participate in health and social integration. Long-term 
residential programmes are best suited for individuals who require intensive and continuing 
treatment to address the whole person, with particular focus on managing complex 
psychological and social problems associated with drug use disorders, and initiating 
changes in multiple life domains to facilitate transition to the process of recovery.  
 
Residential treatment services are typically indicated for individuals:  
 
• experiencing severe drug-related problems that affect their education, employment 
and social integration process,   
• with a history of unsuccessful treatment, who do not respond to pharmacological and 
psychosocial treatment in outpatient or short-term in-patient facilities, 
• affected by severe co-occurring mental health disorders that affect their health and 
security outside of structured environments (who usually require hospitalization), 
• with limited personal resources, 
• with social and family problems and limited social supports,  
• who are socially isolated or marginalized, 
• with difficulties in interrupting their affiliation to criminal groups and drug dealing 
networks,  
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• who recognize the need and are prepared to significantly change life-style and 




The primary goals of long-term residential treatment for patients are: 
• to reduce the risk of a return to active drug use  
• to treat psychiatric and substance/ drug use disorders using medication and 
psychosocial therapy 
• to develop skills to cope with cravings and life stressors without drugs 
• to improve personal health and the family and work environment and social functioning 
• to develop effective interpersonal relationships with other patients and staff while 
acquiring new social skills, gaining self-confidence and receiving appreciation for positive 
behaviors 
• to develop interpersonal and communication skills to build a network of friends who are 
abstinent 
• to acquire a healthier lifestyle e.g. good nutrition, a stable sleep/wake routine, routine 
health monitoring and adherence to treatment 
• to complete their education and develop vocational skills to progressively become able 
to regain control over their life once they return to the general community 
 
3.5.4 Treatment approaches 
 
Long-term treatment programmes may differ in their applied approaches. Treatment may 
begin with a detoxification period, or this may occur prior to admission. Usually in TCs 
treatment consists of a mixture of group and individual interventions, with community 
members sharing the tasks of daily living also as a form of therapy. Interventions offered 
vary significantly and can be based on the 12-step approach or alcoholics anonymous, 
structured psychosocial approaches such as CBT, or a less well-defined approach of the  
collective wisdom of the group. While residents are generally supportive of each other, most 
communities provide a limited scope for provision of critical feedback.  
 
3.5.5 Treatment Methods  
 
Assessment 
An initial meeting allows the staff to become familiar with the prospective resident, and the 
prospective resident to become familiar with the residential programme. It is the first step in 
the development of a therapeutic alliance. During this meeting, prospective residents usually 
decide whether or not to enter the programme, and the programme decides whether or not 
to accept the prospective resident. An initial phone-based interview may be used prior to the 
in-person assessment. 
 
Residential treatment programmes should conduct a comprehensive psychosocial and 
medical assessment of every patient entering the programme to determine individual needs 
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and consider patients’ suitability for the specific treatment programme. Patients with 
significant mental and physical health problems may need a treatment setting which 
provides the appropriate level of medical and psychiatric care.  
Following a patient’s consent, individual needs and medications should be discussed with 
referring agencies and with patients’ medical practitioners, including a plan for detoxification, 
if needed. 
 
Treatment plans should be developed based on comprehensive assessments, which should 
include standardized instruments and procedures such as the Addiction Severity Index (ASI) 
or a Composite International Diagnostic Interview Substance Abuse Module (CIDI-SAM).  
 
The following areas are important for the assessment:  
• Previous short and long-term treatment and perception of previous treatment  
• General health, including current health concerns, physical, sensory, or cognitive 
disabilities 
• Mental health, including trauma and abuse history (physical, emotional and sexual), 
violence and suicide risk, current psychological and interpersonal functioning 
• Current living conditions, including safe accommodation and housing, support 
system at home  
• Family life, including relationships with family of origin, intimate relationships, and 
dependent children  
• Friendships, including network of peer relationships, positive or negative influences, 
and people supporting long-term sobriety 
• Education and work, including school and work history, vocational training level and 
needs, income (legal and illegal)  
• Legal problems, including criminal activity and links to drug use  
• Leisure activities and hobbies  
 
The long-term period and the residential setting create an opportunity for thorough 
evaluation. It also allows evaluation after an initial period of abstinence for drugs, which 
assures that the evaluation is not affected by effects of drug intoxication or withdrawal and 
that patients fully understand the nature of treatment and are able to fully consent to it. Living 
with peers and the staff together allows the evaluation of temperamental and personality 
traits which can be very useful for individualizing the treatment. 
 
Every programme should have a written intake policy to assure that admission to the 
programme is voluntary and confirmed with the written consent of the patient. Such a policy 
should clearly describe the eligibility and exclusion criteria. In addition, programmes should 
have a written intake/orientation procedure, which is used for all incoming residents. During 
the intake procedure, new residents should be well informed and receive written information 
about the programme including its objectives, the treatment methods used, and the 
programme rules. Patients should be informed about their obligations, their rights and the 
details regarding privacy, non-discrimination, and confidentiality. Patients should be 
informed about the role of the staff, the underlying philosophy, and the rules concerning 
communication with people outside the programme and visitors. Finally administrative 
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details (i.e. the programme costs and payment methods) should be discussed. Intake 
policies and procedures should be well known by the staff.  
 
Non-acceptance to a programme 
If a potential resident is not accepted to a programme, a comprehensive explanation of the 
reasons should be given verbally and be provided in written form to the rejected person and, 
if possible (and without breaching patient confidentiality), to the referring agency. If a person 
is not accepted, an appropriate referral must be made. The evaluation staff must be aware 
of appropriate alternative services for referrals with the help of a pre-established network of 
services.  
 
Treatment Engagement  
Higher levels of treatment engagement can influence treatment outcomes positively.  
Variables that foster treatment retention include:  
•  Level of motivation before treatment  
•  Level of drug or alcohol consumption before treatment  
•  Number of arrests before treatment  
•  Strength of the therapeutic relationship  
•  Perceived helpfulness of the treatment service and usefulness of the treatment  
•  Empathy of the staff 
•  Inclusion of relapse prevention training  
 
During the first three weeks and in particular during the first days of treatment, the risk of 
dropout and relapse is highest. Therefore it is important that residents receive individualized 
attention focused on enhancing motivation to remain in treatment. Especially during this 
period many residents may continue to experience psychological distress related to 
protracted withdrawal (insomnia, anxiety, irritability, drug cravings), be ambivalent about 
giving up drugs and may find it difficult to adapt to the rules of the programme. Information 
sessions should cover themes such as: the programme’s philosophy and expectations as 
well as its approach to treatment and recovery, programme’s retention and health outcomes, 
and frequently encountered concerns that residents have during early phases of treatment.  
 
To address wavering motivation and ambivalence about the treatment programme staff 
should:  
• Provide a friendly and welcoming atmosphere  
• Establish a therapeutic alliance built on trust early in the process 
• Respond quickly to requests for treatment to maximize treatment engagement 
• Focus on the client’s immediate concerns, not those of the programme  
• Provide more intensive support during the first 72 hours in treatment through closer 
observation, increased general interaction and the use of a “buddy system” (pairing of 
new resident with an established resident)  
• Be caring and respectful in all aspects of the treatment programme, as confrontation 
often results in anger and early drop out 
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• Give objective feedback about the problems and processes of change in order to foster 
credibility and trustworthiness  
• Develop motivational strategies that focus on the individual patient 
• Develop realistic and personalized treatment goals that reflect the client’s stage of 
change and that are flexible enough to shift as the client progresses  
• Create an awareness of the heterogeneity of clients, particularly in the group treatment 
process  
• Identify multiple strategies for clients with multiple problems  
• Intervene early to reduce confusion and to clarify expectations and roles  
• Manage clients to provide individualized, holistic and ongoing support 
• Develop skills to manage relationships after discharge 
 
Therapeutic Interventions 
At a minimum, long-term residential treatment (mainly those based on the therapeutic 
community model) should provide drug and alcohol free environments, a variety of regular 
group meetings (e.g., morning meetings, non-confrontational groups, special groups for 
female residents, peer evaluation groups), and individual psychosocial support if needed. 
Hospital-based residential programmes should provide medical and psychiatric care, 
individual and group therapy and interventions involving family members.   
 
Long-term residential programmes may include a broad range of therapeutic modalities 
such as individual and group psychosocial intervention, life skills training, vocational and 
educational training and recreational activities. Evidence-based interventions that are 
routinely used in outpatient treatment can be adapted and used in long-term residential 
treatment as well. Specific psychosocial treatment methods that may be utilized include: 
Cognitive-behavioral Therapy, Motivational Enhancement Therapy, and Social Skills 
Training. Structured Relapse Prevention programmes are essential in preparation for re-
integrating residents into the community. Therapeutic interventions such as art and creative 
therapy, movement therapy, meditations, relaxation and physical activity (i.e. exercise and 
group sports) can help patients discover and develop new free time and recreational 
activities, which can support recovery if continued after returning to the community.    
 
As employment is essential to reintegration and recovery, residents are commonly prepared 
for work with education, vocational services and job training. Vocational services include job 
counseling, job interview coaching, resume writing and job application/placement services. 
Job training allows residents to learn skills and develop confidence. Work and educational 
activities, are therapeutic interventions combined with other methods to prepare residents 
to re-enter the community.  
 
Like in any other treatment setting, harsh verbal confrontation or shaming techniques, 
punitive or restrictive techniques (including physical restraints), approaches such as 
counter-conditioning or shock therapy, and any other intervention that compromises 
individual safety or dignity should be avoided.  
 
Length of Treatment  
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A sufficient duration and intensity of treatment increases the chance that any behavioral 
change will be consolidated and internalized, and that residents will be sufficiently prepared 
to live a drug-free life in their communities. The duration of treatment necessary to reach 
this point varies for each resident, however residents who stay at least 3 months in treatment 
usually have better outcomes.  
 
3.5.6 Specific programme requirements 
 
Programmes offering long-term residential treatment for people with drug use disorders 
should include the following components:  
• Comprehensive medical and psychosocial assessment on admission 
• Treatment plan which best addresses individual needs  
• Programme rules that cover clear procedures for admission, discharge and 
consequences for negative behavior 
• Treatment contract which clearly outlines all treatment procedures, services and other 
policies and regulations as well as programme’s expectations of the patient 
• Ongoing evaluation of patient’s progress in treatment, and continuous clinical 
assessment that is built into the programme  
• Relapse prevention and discharge strategies for continuous care after residential 
treatment 
• A clear structure of activities and responsibilities 
 
Documentation 
Written or electronic records of all assessments should be confidentially kept in a secure 
location, only available to the staff directly involved in the treatment. Proper documentation 
should include at minimum: 
• Signed consent to treatment and agreement on programme rules  
• Signed confidentiality and ethics policy  
• Appropriate treatment and management plans for each resident  
• Regular updates with details of treatment, progress and any changes to the original 
goals  
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Staffing 
Some degree of medical supervision is required for therapeutic communities and other long-
term residential treatment services. According to the size of the therapeutic community, 
usually a team of trained professionals and volunteers is necessary for the delivery of 
optimal care.  
 
Medical doctors, including psychiatrists if possible, should be on call or available for a certain 
number of hours every week. In residential treatment facilities of co-occurring mental health 
disorders, medical care services need to be present on site during the day and be “on call” 
availability during the night. Counsellors, nurses and social workers should be present at 
the programme’s site at all times. 
 
Individuals who are themselves in recovery from drug use disorders and who work as staff 
can be valuable role models for residents. Preferably they should have working experience 
outside a treatment programme and follow a professional training as a counselor or group 
worker. For professionals starting to work in a TC it is advisable to spend time in a TC before 
or immediately after being hired. A strict code of ethics for staff should apply. Staff should 
refrain from humiliating or degrading measures and advocating personal beliefs. Optimally, 




All residential treatment programmes must provide a safe environment to staff and residents 
to assure a psychologically and physically safe living and learning environment.  
 
The physical environment and appearance of the programme facility is of great importance, 
as residents may stay for several months. The facility should not look like a prison or a 
hospital but as a home. Absence of alcohol and drugs should be required and assured. 
However, psychoactive medications used under medical supervision to treat psychiatric or 
substance/ drug use disorders, such as methylphenidate, antidepressants, methadone or 
buprenorphine, should not be discontinued unless it is medically indicated. Procedures for 
the dispensing and administering of prescribed medication should be in place.  
 
Behaviours which are not acceptable and may result in the removal from the programme 
include the use of drugs or alcohol, violence, theft and sexual activities between residents. 
Urine toxicology screening on a regular basis, on returning to the community from temporary 
leave and when drug use is suspected, can help to ensure a drug-free environment. 
Procedures to report and deal with unsafe incidents such as physical or sexual abuse should 
be in place. Also for responding to breaches of programme rules and values, clear 
procedures with differing levels of response reflecting the specific circumstances should be 
installed. Contact with visitors should be monitored or supervised, and restricted if 
necessary, particularly in the early stages of treatment.  
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3.5.7 Criteria for programme completion and indicators of effectiveness 
 
During treatment, residents are regularly monitored and periodically evaluated with the goal 
of providing the resident with feedback about their progress towards treatment goals and 
programme completion.  
 
The evaluation of treatment success and readiness for discharge should be on the basis of 
several dimensions including:  
• Improvement of physical and mental health  
• Understanding of factors and triggers that may contribute to drug use and relapse as 
well as demonstration of skills to recognize them and manage drug cravings  
• Improvement of social functioning and willingness to move away from drug using 
networks towards social networks which value abstinence and recovery  
• Development of new hobbies and interests that can be continued after discharge  
• Motivation to continue treatment and recovery maintenance following discharge 
• Ability and motivation to engage in work and to contribute to the community  
 
Some long-term residential treatment programmes offer a transitional or re-entry treatment 
phase to prepare residents for discharge from the programme. During this phase residents 
may gradually spend more time outside the community (pursuing school or work) while still 
residing in the programme. This period of increased contact with the wider community while 
maintaining safety, stability, and support provided by programme services gives residents 
the opportunity to practice newly acquired skills, to maintain abstinence, to develop new 
relationships and supportive friendship networks and, where appropriate, to re-establish 
relations with their immediate families. 
 
 
3.5.8 Rating of the Strength of Evidence 
There is a lack of rigorous controlled studies evaluating the effectiveness of long-term 
residential treatment and specifically the therapeutic community (TC) model. A recent 
Cochrane review found no evidence to say if the TC model is more or less effective than 
other treatment approaches, except for TCs in prisons, which were found to be more 
effective7 than routine medical and psychiatric care in prison.  
 
  
                                            
7 Smith LA, Gates S, Foxcroft D. Therapeutic communities for substance related disorder. Cochrane Database of 
Systematic Reviews 2006, Issue 1.  
 




Therapeutic Community Standards 
• The community has a planned therapeutic programme 
• There is a structured and consistent daily schedule of group activities 
• All members have a written care plan 
• The community prepares members for independent living in the wider community 
• The community has a clear chain of clinical accountability 
• There are clearly defined privileges with a rationale and process for allocating them 
• The community takes responsibility for improving and maintaining patient members’ 
physical health 
• Where patients are offered a pharmacological therapy, there is a written policy and 
adequate clinical oversight 




• The provider has a system laid out that ensures that the method for selecting, hiring 
and training staff corresponds to valid legal norms and established internal rules. 
• The organisation has rules defined that the staff follows in cases where valid 
legislation is too general. 
• The structure and management of the organisation is defined, making competences 
for individual positions clear. 
• The provider has specified the structure and staffing needs, as well as corresponding 
job profiles and staff qualifications, taking into account the needs and current number 
of service users for service organisation. The composition and additions to the team 
correspond to these needs. 
• Prevention of work risks has been secured. 
• Cases where a patient’s rights have been violated by an employee and the 
corresponding measures that were taken are documented in personnel records. 
• Specialised care (medical, psychological, psychotherapeutic, social, educational 




• There are defined criteria for the expulsion of patients due to violation of treatment 
service rules, violence, continued non-prescribed drug use, etc. 
• There are defined criteria for the management of specific risk situations (e.g., 
intoxication, suicide risk) 
• Discharge is based on a consideration of patient recovery status 
• Attention is paid to further treatment and support (e.g., family, social) which may be 
required, based on patient’s diagnoses, goals, and resources 
• Care plans are explored which map out alternative pathways which might be followed 
in the event of partial or complete failure of the original plan, or expulsion from drug 
treatment services 
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3.6 Recovery Management 
 
 
3.6.1 Brief Definition and Description of the Setting  
 
Recovery management, also known as “aftercare”, “continuing care” or social support, 
describes a long-term recovery-oriented model that follows stabilization of abstinence 
achieved during outpatient or residential treatment. It focuses on reducing the risk of relapse 
to drug use by comprehensively supporting social functioning, well-being, as well as social 
reintegration into community and society. Recovery management helps to stabilize and 
strengthen recovery following a life course perspective. By building on the strength and 
resilience of patients the focus is moved to the patient, which increases their sense of 
personal responsibility for managing their drug use disorder. 
 
Longitudinal studies have repeatedly demonstrated that the treatment of drug use disorders 
is associated with major reductions in substance use, drug-related problems, and costs to 
society. However, post-discharge relapse and eventual re-admission are very common, so 
that the majority of patients admitted to treatment have received treatment before. The risk 
of relapse appears to decrease not until 4 to 5 years of successful abstinence. A sustainable 
recovery however is possible, and up to 40% of patients with drug use disorders achieve it. 
  
Ideally, long-term residential and intensive outpatient care should both be followed by a step 
down to a less intensive level of care that continues long-term. This is opposed to repeated 
brief episodes of care following each relapse that lack continuity. Recovery-oriented 
continuing care is an approach to long-term management of patients within the network of 
community-based supports and services. Professionally directed recovery management, 
like the management of other chronic health disorders, shifts the focus of care from one of 
“admit, treat, and discharge” to a sustained health management partnership. In this model, 
the traditional discharge process is replaced with post-stabilization monitoring, recovery 
education, recovery and coaching, active linkage to communities of recovery, recovery 
community resource development, and early re-intervention when needed.  
 
The focus on long-term management as opposed to single-episode treatment is supported 
by the evidence that drug dependence is best understood and managed as a chronic and 
relapsing disorder rather than an acute illness or episode, similar to diseases like 
hypertension, asthma and diabetes. Therefore medical and psychosocial interventions 
should be available for individuals affected by drug use disorders over a lifetime, with 
intensity matching the severity of symptoms. Recovery management approaches should 
include long-term pharmacological, psychosocial, and environmental interventions targeted 
at reductions in substance use and criminal behavior as well as improvements in physical 
and mental health, and social functioning.  
 
  




The primary goal of recovery management is to maintain benefits obtained in earlier 
treatment. After being able to maintain abstinence and control compulsive drug-seeking 
behavior, during intensive treatment stages, recovery-oriented care aims to support the 
development and consolidation of personal and social assets that are necessary to cope 
with external circumstances and maintain a healthy lifestyle. This includes ongoing pursuit 
of personal and social recovery as a part of living a drug-free life, improvement of self-care 
for physical and psychological well-being, reclaiming personal dignity, self-worth, and 
spiritual growth.  
 
Recovery can be supported by regular contact with treatment (including medication and 
regular therapy) and/or maintaining engagement with a broader recovery community such 
as mutual-support groups. Recovery-oriented care supports the development of skills to 
manage daily stress related to homelessness or the maintenance of housing, unemployment 
or workplace problems, social isolation or unsatisfactory interpersonal relationships. In 
particular, patients need support prior to and during crises and conflicts to help control 
dysfunctional and emotionally intensive reactions. Through all these elements recovery 
oriented treatment supports a focus on reducing stressful stimuli that may provoke the 
recurrence of compulsive drug seeking. In general, recovery-oriented care assists patients 
in improving and stabilizing a good quality of life and opportunities for social reintegration in 
the community. 
 
In addition, the resurgence of psychiatric symptoms that have been “masked” by drug use 
must be anticipated and identified during early recovery. This allows for the appropriate 
provision of treatment and care, including pharmacological and psychosocial interventions.  
 
3.6.3 Types of patients this treatment modality is best suited for  
 
After initial treatment of drug use disorders the majority of patients need some degree of 
long-term recovery management, at an intensity matching the needs of each individual. 
Patients with a history of multiple relapse episodes, physical and mental health disorders, 
poor family and community support, financial, legal and/or housing problems, are in special 
need of recovery management. Patients with high disorder complexity, in particular those 
with an early onset of drug use disorders and global impairment of functioning, low effective 
life skills and limited coping mechanisms for stress, are in need of more intensive recovery 
management programmes. It is important that patients with a high vulnerability for relapse 
are connected with appropriate and personalized components of recovery management 
before discharge from long-term residential or intensive outpatient treatment. 
 
3.6.4 Treatment Models and Methods  
 
Continuing Care and Recovery Management (RM) offers to patients the opportunity to 
maintain ongoing contact with the health care system, social services and treatment 
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facilities. Commonly a counsellor would coordinate the case management, meet the patient 
frequently, provide positive support, encourage engagement in the community and help to 
manage stressful situations which arise. A counsellor helps the patient to connect with other 
professionals who can be helpful in the process of social reintegration. In response to 
specific needs, a counsellor refers patients in particular to social workers and psychologists, 
medical practitioners, sex and reproductive health professionals and legal services officers.  
 
Principles of recovery management  
The recovery management approach is characterized by:  
 
Focus on increasing strengths rather than reducing deficits. Recovery-oriented approaches 
seek to identify, support and develop skills, talents, resources, and interests instead of 
emphasizing needs, deficits, and pathologies. 
 
Flexible rather than fixed programmes. Recovery management programmes must respond 
to patient changes through modifications made over time, offering choice by providing a 
flexible range of support and services to meet needs of the individual patient.  
 
Consideration for patient’s autonomy. Recovery management is a self-directed approach 
that encourages and supports the making of informed choices about their life and the 
treatment. The importance of incorporating patients’ choices has been stressed in other 
areas of medicine, especially in the management of chronic diseases, and was found to 
increase individual’s responsibility for their recovery. 
 
Participation of community. As opposed to overcoming dependence in isolation recovery 
management tries to involve family members, friends, and the community to strengthen 
social aspects of recovery. Others are encouraged to play a role in the recovery process 
and resources of the community are used such as professional and non-professional 




Recovery management combines a variety of activities that promote and strengthen internal 
and external resources to help patients manage voluntarily and actively drug-related 
problems and their recurrence. Some of these activities may be already present in the 
context of a patient’s home, neighborhood and community while others need to be 
developed. The following factors and activities increase social reintegration and improve 
chances of stable remission and recovery from substance use disorders:  
• Strengthening individual’s resilience, self-efficacy and self-confidence to manage 
daily challenges and stress while maintaining commitment to recovery and avoiding 
relapse to substance use  
• A supportive social network (i.e. partner, family members and friends) that can 
monitor the stability of recovery, abstinence from drugs and compliance with 
treatment 
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• Engagement with individuals and social networks of friends and workmates that have 
abstinence-oriented norms and are supportive of recovery goals  
• Meaningful and appreciated work that replaces stigma and discrimination  
• Social participation and integration in educational and vocational pursuits, including 
volunteering or community involvement  
• Active involvement in self-help, religious or other support groups 
• Political, humanitarian or spiritual involvement that provides a way to achieve a 
stronger purpose in life  
• Stable accommodation 
• Remediation of legal and financial problems  
 
Specific Requirements 
Treatment plans should be developed with the help of a team of professionals with patients 
being involved. Treatment plans should be individualized and consistent with the 
management of other chronic illnesses. In contrast to intensive care programmes, treatment 
plans in recovery-oriented care expand their focus from primarily medical care to social care 
including other professionals (e.g., social workers, psychologists, peer counsellors, and 
potentially also tribal elders, religious leaders, and other community leaders), as well as 
friends and supportive family members.   
 
Recovery management treatment plans usually involves a regular monitoring or follow-up 
evaluations that can be done by a counsellor, psychologist as well as specialist or a primary 
care physician. Such recovery checkups, done in person or by phone, can promote 
sustained recovery and prevent relapse. During the checkup, the counsellor may ask the 
patient to provide an update on their work performance, living conditions, coping 
mechanisms with stress, or maintaining healthy relationships. With recovery checkups, that 
may include voluntary toxicology testing, patients can be screened for relapse while living 
in the community and if needed receive early re-intervention.  
 
3.6.5 Criteria for programme completion and indicators of effectiveness 
 
As the recovery management approach adopts a “life course” perspective, it is open-ended 
and may continue for an entire lifetime. Terms of “discharge” or “graduation” used in more 
traditional treatment models are therefore not utilized. It embraces the chronic disease 
management approach that aims to help individuals effectively manage their own health 
problems with the goal of improving their well-being.  
 
The success of recovery management programmes should be evaluated with respect to its 
capacity to reduce relapse rate (controlling drug use and avoiding associated harms) and 
improve physical and psychological health, well-being, social functioning and reintegration. 
Structured instrument that evaluate global functioning such as the Addiction Severity Index 
can be used to assess the progress in multiple dimensions of health and functioning while 
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other instruments can assess the “recovery capital”, which is the amount of internal and 
external resources that can be used to initiate and sustain recovery.  
 
3.6.6 Rating the strength of evidence 
 
Recovery Management is a new and evolving conceptualization of long-term treatment of 
drug use disorders that does not stop after a single treatment episode, or after a short-term 
aftercare programme. It is more a treatment approach than a specific intervention and has 
not been compared to other treatment approaches through Randomized Clinical Trials 
(RTCs).  
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Chapter 4: Special Populations 
 
 
4.1 Treatment of pregnant women 
 
4.1.1 Treatment Principles 
 
Women with drug use disorders who are pregnant represent a unique population in special 
need of treatment for two reasons. First, pregnant women with drug use disorders present 
a challenge to health service providers, because drug use may impact both the mother and 
the fetus – and, because treatment may also adversely affect both members of the dyad. 
There are medical and ethical challenges that come with providing treatment for drug use 
disorders to a dyad, in comparison to a mother and a child separately. Second, the majority 
of pregnant women with a drug use disorder have few if any parenting skills, and may lack 
basic knowledge about child development and childrearing. Moreover, once the baby has 
been delivered, the child may need medical and other comprehensive services, given the 
possibility of having experienced adverse fetal circumstances. On the other hand, the 
opportunity to provide treatment for substance use disorders to pregnant women has 
tremendous potential for positive life-improving changes for the mother and the fetus and 
the mother and the child if the child is provided services too. Thus, there are often two ‘dyads’ 
that are involved in treatment of pregnant women with substance use disorder – the mother-
fetus dyad, and the mother-child dyad.  
 
Issues for pregnant women with drug use disorders mirror the issues for drug-using adults. 
Several of these issues, such as the lack of formal education or likely legal involvement, are 
common to men, women and pregnant women. In contrast stigma, shame and the lack of 
positive and supportive relationships are issues which may have a more adverse impact on 
women, which are key reasons why women often do not seek, enter or engage in treatment. 
Women are more likely than men to have experienced child abuse and/or neglect, 
undergone repeated exposure to interpersonal violence, be economically dependent on 
others for survival, have not been able to access formal educational or vocational 
opportunities, and have limited parenting skills and resources. With pregnancy the above 
mentioned issues may become even more prominent and present barriers to treatment 
entry, engagement and outcomes. Unlike other individuals who use drugs, pregnant women 
are exposing their fetus to potential harmful substances. The vast majority of these women 
are conflicted, ashamed, and guilt-ridden about what they often see as their inability to 
‘control’ their substance-using behavior. 
 
The World Health Organization has recently stressed the unique needs of treatment 
services for pregnant women with drug use disorders. Pregnant women with drug use 
disorders have the same rights for treatment as non-pregnant persons and pregnant women 
without substance use disorders and should not be ejected from treatment nor prevented 
from receiving treatment because of pregnancy. Treating women for drug use disorders is 
not more complicated than treating other populations of patients. Women with a drug use 
disorder should not be forced to have involuntary abortions and sterilizations. Moreover, 
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treatment programmes must have procedures and safeguards in place to prevent detention 
and forced treatment of pregnant women. Finally, women have better long-term outcomes 
when they receive treatments that focus on the issues more commonly found in women with 
drug use disorders compared to treatments that lack such a women-centred focus. 
 
 
4.1.2 Treatment Methods   
 
Screening and Intake 
Services that provide treatment to pregnant women with drug use disorders and their 
children typically have a screening and intake procedure that allows for determination of 
suitability for entry into the programme. At minimum, screening should assess three risk 
factors: urgent medical attention, detoxification and prevention of harm to self and/or others. 
Any one or more of these three risk factors might indicate that a pregnant woman may be 
referred or transferred to a more specialized medical or psychiatric unit to manage these 
risks, at least on a short-term basis, prior to entry into the treatment programme. Pregnant 
women’s needs and whether these fit with the services provided by the programme should 
be considered the first step in establishing a patient-provider relationship and a chance to 
build rapport.  
 
A written policy regarding screening and intake procedures should exist and include the 
following elements:  
• Description of the screening procedures and intake measures and/or interviews. To 
the extent possible, all intake measures and interviews should be validated in 
pregnant women with substance use disorders.  
• Staff training requirements to conduct intake and screening.   
• Policy regarding eligibility for admission to the programme and procedures for non-
admission including information about alternative services for pregnant women. 
 
All clinical information should be kept in a safe and secure location, and entered into 
patient’s program records. 
 
Assessment 
Clinical assessment occurs on entering the programme examining the pregnant woman’s 
life in detail for 3 purposes:  accurate diagnosis, appropriate treatment placement, and 
development of appropriate treatment goals. The primary purpose of an assessment is to 
evaluate current life circumstances and gather information regarding physical and 
psychological health, substance use, family support and social history so that a treatment 
plan can be developed that matches her strengths and needs. Pregnancy specific 
information such as the due date, past pregnancies and plans to deliver are also important. 
An assessment should utilize multiple sources of information to obtain a complete history of 
the woman. There should be an initial assessment and then it should be seen as a fluid 
process, and assessment should be periodically planned to occur during treatment. Given 
changes in physical,  psychological and social functioning, it is critical to assess a woman 
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throughout treatment, and as she enters recovery. How frequently such assessment should 
be undertaken would depend on the clinical course of treatment and the occurrence of any 
setbacks in the treatment progress. Standards for assessment are similar to those standards 
for screening and intake as described above. 
 
Treatment Planning 
A pregnant woman with a drug use disorder should not be seen as a passive patient who is 
only informed of her health status. Rather, she should be actively participating in treatment 
decisions that affect not only herself but also her child. 
  
Treatment Approaches 
Treatment approaches for pregnant women with drug use disorders depend in large part on 
the drug(s) that are used, and the amount of such use. In certain circumstances a brief 
intervention that focuses on education and risk review and is provided by a primary care 
provider or obstetrician may be appropriate. However, given the potential risks to the fetus, 
such interventions need to be limited to very selective cases with only problematic substance 
use or mild drug use disorder. As such, most treatment programmes for substance-using 
pregnant women utilize more traditional treatment approaches.   
 
There are two distinct dimensions that can be used to organize such treatment programmes: 
Setting and Type of Intervention. On one end of the treatment setting continuum are 
outpatient treatment programmes; on the other, full-time residential programmes. Treatment 
interventions include pharmacotherapy and psychosocial interventions.  
 
Special considerations for pharmacological treatments during pregnancy 
Pharmacological considerations are especially important for women with opioid use disorder 
where medication assisted treatment is essential. Women should not be denied treatment 
with opioid agonist medication only because of pregnancy. Opioid medication choices 
should be made on a patient by patient basis considering individual characteristics. Both 
methadone and buprenorphine are effective treatments with favorable risk to benefit ratio 
but their effects are not always comparable in every patient. Research evidence shows that 
buprenorphine exposure in utero leads to less severe neonatal abstinence syndromes 
(NAS) than methadone. However, NAS is an easily identifiable and treatable condition that 
is only one aspect of the complete risk and benefit ratio decision to consider for a woman 
and her physician when making medication decisions during pregnancy. 
 
Both methadone and buprenorphine effectively reduce opioid use and allow patients to 
further benefit from psychosocial treatment. Medication dose should be re-assessed 
periodically during pregnancy for adjustments, usually upward, in order to maintain 
therapeutic medication plasma levels and thereby minimize the risk of opioid withdrawal and 
craving and reduce or eliminate drug use and maintain abstinence.  
 
If a woman becomes pregnant while on either methadone or buprenorphine, treatment 
should be continued on the same medication, especially when treatment response is good. 
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Medical withdrawal from opioid agonist during pregnancy is not recommended. Withdrawal 
is associated with high rates of treatment dropout and relapse with associated risk to the 
woman and the fetus, and opioid withdrawal increases the risk of miscarriage.  
 
Comprehensive Treatment 
A comprehensive women-centered treatment approach consists of treating the whole 
person and the mother-child dyad. This includes trauma-informed group and individual 
treatment, childcare, transportation, medical care, obstetric and gynecology care, 
psychiatry, parenting education, early intervention, vocational rehabilitation, housing, and 
legal aid. Providing these services is necessary but not sufficient to make a treatment 
women-centered. Women-centered treatment programmes for drug-using pregnant women 
need to be sensitive and deal with the following specific biological as well as cultural, social, 
and environmental factors related to drug use and treatment in women in order to optimize 
the outcome of treatment.  
 
Other consideration in the treatment of women with drug use disorders include: 
 
• Significant interpersonal relationships and family history play an integral role in the 
initiation of drug use  
• Stigma deters treatment entry for women 
• Women often enter treatment for drug use disorders from a wider array of referral 
sources 
• Women are more likely to encounter obstacles in seeking and during treatment as a 
result of caregiver roles, gender expectations, and socioeconomic hardships. These 
barriers may result in a delayed treatment entrance at a more severe stage of the 
disorder with additional medical and psychiatric pathology 
• Women are more likely to engage in help-seeking behavior and in attending 
treatment after admission 
• Pregnant women may require adjustment of medication dosages  
• Women may require women-focused treatment in a safe single-sex setting to obtain 
maximum benefit 
• Women may need training and support on issues such as sexual health, 
contraception, parenting and child care   
• Women and children are more vulnerable to risk of domestic violence and sexual 
abuse, therefore a liaison with social agencies protecting children and women is 
helpful 




 UNODC-WHO International Standards for the Treatment of Drug Use Disorders 66 
 
Delivery Protocol 
Programmes that include delivery services for pregnant women with drug use disorders 
should have a written delivery protocol that specifies potential issues with both delivery and 
patient management. At a minimum, discussion of where delivery will be conducted, who 
will be notified, what provisions she and her child need and how she will get these provisions 
should be included. Appropriate pain management procedures must also be in place. Many 
women with opioid use disorders are actually more sensitive to pain than women without 
such disorders. Untreated pain can trigger drug use relapse and other adverse outcomes 
for the mother and the infant if the mother is not able to care for the child. 
 
Postnatal Treatment Protocol 
All programmes that provide services to pregnant women with drug use disorders should 
have a postnatal treatment protocol in place. Women should not be discharged from 
treatment due to pregnancy or postpartum status alone. Methods to support the mother-
infant dyad, including at least basic parenting skills, should be also outlined. 
 
Breastfeeding 
Although every effort should be made to encourage breastfeeding in drug-using mothers, 
the decision about breastfeeding should be evaluated on a case-by-case basis. 
Breastfeeding may be contraindicated in the case of HIV-positive mothers and for mothers 
with other medical conditions who take certain psychotropic medications. Other 
contraindications or precautions regarding breastfeeding occur in the case of maternal use 
of inhalants, methamphetamines, stimulants, tranquilizers, and alcohol.   
 
Specific guidelines on this issue have been published to help physicians make the best 
recommendation. The need for a case-by-case approach to breastfeeding in the case of 
substance-using mothers is based on an assessment of the mother’s understanding of the 
impact of the substance secreted in breast milk as well as her substance use practices. It is 
suggested to reach clear, written agreements with mothers about their breastfeeding 
practices. 
 
4.1.3 Specific requirements for the programme 
 
Staff Training 
Any staff member who has direct contact with patients (secretaries, office managers) must 
be knowledgeable and sensitive to the issues pregnant women face. Staff should be trained 
on what to do when a woman goes into labor: who to contact, how to react, where to go for 
medical help. Unlike other individuals who use drugs, pregnant women are exposing their 
fetus to potential harmful substances. The vast majority of these women are conflicted, 
ashamed, and guilt-ridden about what they often see as their inability to ‘control’ their drug-
using behavior. Staff need to be aware of these feelings and concerns and be prepared to 
respond appropriately in a supportive way. Shaming and stigmatizing women for drug use 
during pregnancy is not an effective treatment method for preventing drug exposure to the 
fetus or improving the health of the mother. 




Regardless of the type of setting or intensity of care provided, proper documentation of the 
treatment of pregnant women with drug use disorders should include all of the elements 
specified for the general population of patients with drug use disorders, i.e. treatment 
contract, individualized treatment and management plan, and a treatment completion 
summary. Services providing care to pregnant women with drug use disorders need to 
properly keep records of all medical, psychiatric, and treatment services to assure close 
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The number of neonates born following intrauterine chronic exposure to opiates and other 
substances is difficult to determine. Factors contributing to this imprecision include lack of 
measurement and alterations in drug-taking patterns over time, and geography. The 
outcome of newborn infants is enhanced if comprehensive medical, psychosocial and 
medication assisted treatment is provided for their mothers. When these services are not 
provided, the newborn infant is at risk for prematurity, Intrauterine Growth Restriction 
(IUGR), neonatal sepsis, stillbirth, perinatal asphyxia, poor mother–infant attachment, 
deprivation, neglect, Failure to Thrive, and Sudden Infant Death Syndrome (SIDS). One of 
the major conditions that may exist in 50-80% of in-utero opioid-exposed newborns is 
Neonatal Abstinence Syndrome (NAS). NAS is defined as transient alterations in the central 
nervous system (e.g., irritability, high pitched cry, tremors, hypertonia, hyperreflexia, sleep 
disturbances), gastrointestinal system (e.g., regurgitation, loose stools, increase sucking 
reflex, dysrhythmic sucking and swallowing, poor intake with weight loss), respiratory 
system (e.g., nasal stuffiness, tachypnea), and the autonomic nervous system (e.g., 
sneezing, yawning), that manifest in the days and weeks following birth in babies exposed 
to opioids or other sedatives in utero. Newborn babies develop NAS from maternal use of 
illicit opioids purchased on the street or from prescribed medication given by the mother’s 
physician for her medical condition including methadone or buprenorphine used to treat her 
opioid use disorder.  
 
Treatment of Neonatal Abstinence Syndrome (NAS) 
Treatment of NAS should include non-pharmacological interventions followed by medication 
treatment (when needed) after proper and consistent assessment. Supportive measures 
include: rooming-in, breastfeeding, offering a pacifier (non-nutritive sucking), swaddling 
snugly with hands available for sucking without overdressing, and skin to skin contact with 
the mother. Newborns naso-pharynx should be aspirated and feeding should include 
frequent offerings (every 2hrs) of small amounts (if poor feeding persists) without 
overfeeding with positioning right side-lying to reduce aspiration if vomiting or regurgitation 
are prominent symptoms of NAS.  
 
Initiation of pharmacological treatment of NAS should not be delayed. The most commonly 
used medications for NAS due to opioid exposure are oral morphine or methadone 
according to body weight and score. With neonatal abstinence from other substances (e.g. 
barbiturates, ethanol, and sedative hypnotics) generally phenobarbital is administered. The 
goal of medication is to alleviate the symptoms of abstinence and calm the baby so that the 
usual functions of eating, sleeping and elimination are normal. The medication dose should 
be promptly escalated when needed, preferably in response to the frequent assessments of 
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Staff Training 
All health care staff caring for infants should be trained to identify the signs and symptoms 
of NAS as well as the neonatal conditions that may present in similar ways as NAS (e.g., 
septicemia, encephalitis, meningitis, post-anoxic CNS irritation, hypoglycemia, 
hypocalcemia, and cerebral hemorrhage).   
 
Documentation 
Any assessment for NAS should be recorded as should the medication and non-medication 
interventions provided to minimize NAS. 
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4.3 Children and Adolescents with Substance Use Disorders 
 
 
4.3.1 Treatment Principles 
 
Types of children and adolescents who may present to treatment  
Children and adolescents around the world comprise a large majority of the victims of 
neglect and physical, sexual and emotional abuse. Children are used in war, terrorism, are 
subjected to many forms of violence, are kept illiterate, trafficked for profit, and used in the 
drug trade. Children suffer deprivation, poverty, famine, gender-based discrimination, 
displacement and various mental and physical health conditions. Children are victimized at 
each point of the drug trade industry, they are used in the growing, manufacturing, selling, 
buying, and in distribution. Children whose families grow drug-producing plants are exposed 
to toxic residues and second and third-hand smoke. Children living in countries of conflict 
are made vulnerable to dire risks in multiple ways. Child soldiers have easy access to drugs 
to keep them awake, make them fight, and perform other terrorizing behaviors as well as 
deal with trauma of violence. For them, drug use is used as a way to find temporary solace 
in an unsafe and unpredictable world. 
 
Issues to Consider when Treating Children and Adolescents  
Substance use disorders are critical paediatric illnesses. The earlier substance use starts, 
the greater the risk for more rapid progression to heavy use and use disorders. Children 
who use drugs are unlikely to identify it as a problem for themselves or others in their lives; 
however, drug use – both licit and illicit -- can harm the development of a child. Moreover, 
such children will very likely be in need of substance use and mental health treatment 
services in the future.   
 
Children may reside with their families but may also live on the streets, being orphaned or 
rejected from their family, may be conscripted into the military, or live in correctional system 
institutions. As a result, treatment circumstances and settings for these latter two groups of 
children may be quite different than traditional outpatient or residential treatment, and may 
involve more outreach and drop-in centers than is typically found in treatment of substance 
use disorders of adults. Adolescents may be brought to treatment by their parents who are 
concerned about recent drug use. 
 
Research on the treatment for this population is limited and although there is encouraging 
evidence that psychosocial treatment is effective in older children, guidance regarding 
treatment for younger children has often been based on research findings from treatments 
provided to adults or adolescents. However, such an approach to treat children with drug  
use disorders may present unanticipated problems such as different response to 
medications in children in contrast to adults. Finally, many psychosocial treatments used 
with children need to be tailored to the level of cognitive development and life experiences 
of the children.  
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Other issues to consider when providing treatment for substance use disorders in children 
and adolescents include:  
• Children and adolescent drug users have unique treatment needs related to their 
immature brain and cognitive functioning and limited coping skills related to 
incomplete psychosocial development; 
• Adolescents have high levels of risk-taking and novelty seeking and are very 
responsive to peer pressure; 
• Adolescents with drug use problems have high prevalence of comorbid psychiatric 
disorders and family dysfunctions which need to be a focus of treatment; 
• Children and adolescents may be less likely than adults to see the value of talking 
about their problems, they are more concrete in their thinking, less developed in their 
language skills, and may be less introspective than adults; 
• Behavioral treatment interventions must be adapted taking into account the limited 
cognitive abilities of children and adolescents; 
• Children and adolescents may have different motivations than adults to participate in 
treatment and to share common treatment goals with a treatment provider. 
 
Adolescence is an important developmental period and adolescent brains are especially 
vulnerable to drug use disorders. Given the neurotoxic effects of drugs or alcohol on 
developing brain, substance use needs to be identified and addressed as early as possible. 
Adolescents can also benefit from interventions for substance use even if they are not 
dependent on any specific substance. Disrupting exposure to the substance as soon as 
possible may help minimize the risks for subsequent physical and/or psychological damage. 
Routine medical, school, or other health-related visits provide opportunities for asking 
adolescents about substance use and adolescents will respond honestly if they do not 
perceive immediate negative consequences for being honest. Legal, school, and family 
pressure can be important forces to have adolescents enter, stay in, and complete 
treatment.  
 
Treatment of drug use disorders should be tailored to the unique needs of the adolescent 
and address the needs of the whole person, not only the drug use. Violence, child abuse, 
and risk of suicide need to be identified and addressed early in treatment. Monitoring 
substance use is key to treatment of adolescents, where the goal is to provide the needed 
support and additional structure while their brains are developing. In treatment, adolescents 
need more and different support than adults do. Given the onset of sexual involvement and 
higher rates of sexual abuse among adolescents with drug dependence, testing adolescents 
for sexually transmitted diseases such HIV, as well as Hepatitis B and C, is an important 
part of drug treatment. Treatment should also include strategies such as: social skills 
training, vocational training, family-based interventions, sexual health interventions 
including prevention of unwanted pregnancy and sexually-transmitted diseases.  
 
Treatments should attempt to integrate other areas of social involvement of adolescents 
such as school, sports, hobbies and recognize the importance of positive peer relationships. 
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Treatment of adolescents should promote positive parental involvement where appropriate. 
Access to child welfare agencies must be available. 
 
Drug use disorder and mental health treatment services should accommodate the unique 
characteristics and be flexible in identifying and addressing the needs of children and 
adolescents within a framework that best protects a child from harm and meets their 
individual health needs.   
 
4.3.2 Treatment Methods  
 
Outreach Services  
The goal of outreach programmes is to identify children who might be in need of health-
related services, and provide such services to the extent possible, given the constraints 
under which a child might be living (e.g., on the streets, incarcerated). Thus, outreach staff 
intend to target children known to be at risk, and then to serve as a conduit for necessary 
services. These services would be intended to address any of a variety of problems, 
including health-related and mental-health-related treatment services. In outreach cases, 
screening may be conducted by interview on the part of the outreach staff, and its goal is to 
collect sufficient information to determine the need for referral and treatment in multiple 
areas known to be problematic for children in such circumstances where contact is made 
(e.g., street) and to be an active agent in arranging for such treatment. The cause and extent 
of the problem are secondary to simply initiating treatment.   
 
Screening and Assessment  
Traditional inpatient and outpatient programmes that provide treatment to children will 
typically have screening and intake procedures that determine suitability of the child for entry 
into the programme. Thus, screening for three risk factors, at a minimum, is necessary as 
part of the admissions process: intoxication, threat for self-harm and/or harm to others and 
abuse (emotional, sexual and/or physical). Any one or more of the problems might suggest 
that a child be admitted to a more suitable in-patient treatment. An assessment evaluates a 
child’s current life circumstances and gathers information regarding the physical, 
psychological, family, and social history to determine specific treatment needs, so that a 
treatment plan can be developed that matches the strengths and needs. Standards use in 




Children with drug use disorders need to be considered as part of a treatment team that 
focuses both on the physical and psychological well-being. A child should not be viewed as 
a patient to be passively informed of her/his health status, rather, the child should be seen, 
along with the caregiver, as actively participating in treatment decisions. Additionally, early 
on in the planning process, decisions should be made regarding transitioning back to the 
community.   
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Treatment Approaches 
Treatment approaches for children with drug use disorders depend in large part on the 
substance(s) that are used. As with other patient population, treatment should involve 
psychosocial interventions in combination with medication when appropriate. However, 
there is little research regarding the efficacy of these pharmacotherapies in the treatment of 
adolescents and even less with child substance use disorders and therefore none of the 
medication are approved for use in this population. There is some support for the use of 
opioid agonists, such as methadone and buprenorphine, in adolescents when they are 
considered able to consent to such treatment and it should be used for adolescents with 
severe opioid dependence with high risk for continuing drug use. The consent to any 
treatment of minors should be provided also by parents in compliance with national 
legislations. Adolescents with a short duration of opioid use disorder who have a significant 
family and social support may respond to opioid withdrawal with or without naltrexone as a 
relapse prevention strategy. Appropriate pharmacotherapy should also be used to treat co-
occurring psychiatric disorders as a part of integrated treatment plan that also involves 
psychosocial treatments.  
 
Psychosocial approaches for the treatment of drug use disorders in children and 
adolescents should cover a wide range of their lives as possible using an individualized 
approach that takes into account their vulnerabilities and strengths. Examples of treatment 
approaches for substance use disorders in children and adolescents include the life skills 
approach, family-based interventions (e.g., brief strategic family therapy, family behavior 
therapy or multisystemic family therapy) and basic education. Adolescents will benefit from 
training in self-control, social skills, and decision making. 
 
Gender-specific Issues in the Treatment of Adolescents 
Recognition of gender differences should be included as an integral part of treatment in 
adolescents. Boys typically prefer mixed-gender groups, while girls prefer girls-only groups, 
reflective of differences in both the socialization and substance use histories of girls and 
boys. Given the much higher rates of physical abuse, sexual abuse and the exchange of 
sex for drugs among girls than boys, at least part of a treatment programme should be 
gender-specific. In girls, treatment may focus on unique vulnerabilities of girls such as 
depression and a history of physical and sexual abuse, while in boys treatment may focus 
on impulse control issues, disruptions in the school and the community, and a history of 
learning and behavioral problems however many of these issues will need to be addressed 
in all children.  
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4.4 Treatment of People with Drug Use Disorders in Contact with the 
Criminal Justice System 
 
4.4.1 Brief definition and description of the setting  
 
Over 10 million people are incarcerated worldwide (approximately 146 per 100,000 
inhabitants) and in most countries, the majority of these individuals have a history of drug 
use. Also, a large percentage of individuals with drug use disorders who are not currently 
incarcerated report having been incarcerated at least once. 
  
It should be noted that with regard to offences of possession for personal consumption the 
international drug control conventions8 foresee the provision of measures such as treatment, 
education, aftercare, rehabilitation or social reintegration, including as complete alternatives 
to conviction or punishment.9 In addition to the international drug control conventions, States 
have a range of standards and norms related to the application of non-custodial measures, 
which they should draw upon.10  
 
Persons with drug use disorders who come into contact with the criminal justice system can 
be offered drug treatment services, which at the same time possibly also addresses an 
essential factor in reoffending risk. By making sure that people with drug use disorders in 
contact with the criminal justice system have access to evidence-based treatment and care 
services, significant decreases in drug use disorders, and directly related criminal activity, 
are likely to occur and positive public health outcomes would be expected (e.g. decreased 
spread of Hepatitis C, HIV). Left untreated, individuals who have an extensive drug use and 
related criminal history are more likely to continue their activities, thus posing an ongoing 
threat to public health and security. 
 
Treatment of people with drug use disorders in contact with the criminal justice system may 
– depending on the offence – take place as an alternative to conviction or punishment or in 
addition (e.g. in prison). Treatment as an alternative to conviction or punishment takes place 
under a variety of conditions, such as probation or parole, diversion and drug treatment court 
programmes, or police referral to treatment, as appropriate. In closed settings, such as 
prisons and pretrial places of detention, the criminal justice system addresses persons that 
to a large extent may benefit from access to effective drug dependence treatment services, 
as appropriate.  
 
                                            
8 The international drug control conventions are the 1961 Single Convention on Narcotic Drugs as amended by its 1972 
Protocol (1961 Convention); the 1971 Convention on Psychotropic Substances (1971 Convention); and the 1988 United 
Nations Convention Against the Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1988 Convention). 
9 See article 36(1)(b) of the 1961 Convention, article 22(1)(b) of the 1971 Convention, and article 3(4) of the 1988 
Convention. 
10 See, notably, the United Nations Standard Minimum Rules for Non-custodial Measures, General Assembly resolution 
45/110, annex (the Tokyo Rules); and the United Nations Rules for the Treatment of Women Prisoners and Non-
custodial Measures for Women Offenders, General Assembly resolution 65/229, annex (the “Bangkok rules”). 
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Providing drug treatment and rehabilitation services in the context of the criminal justice 
system must be based on the same principles as for any field of medical practice. In addition, 




Evidence-based approaches, including interventions based on an assessment of an 
individual’s risk of recidivism, can be effective in breaking the drug use and crime cycle. An 
important aspect of selecting these interventions is to provide individuals with the most 
appropriate type and intensity of services. Providing low intensity treatment services to those 
who have serious drug-related problems typically fails to result in the desired outcomes. 
Similarly, providing high intensity treatment services to those with less serious drug-related 
problems can also be problematic, and can occasionally make the situation worse by 
exposing the individual to people with higher risk patterns of drug use. Matching individuals 
to intervention services and the tailoring of services to specific risks and needs should be 
based on matching the intensity of the individual’s problems to the type and intensity of the 
services that are provided.  
 
4.4.3 Types of clients  
 
Evidence-based treatment and care needs to be available to all people with drug use 
disorders independent of their legal status. Considering people who use drugs and those 
with differing degrees of severity of drug use disorders without any criminal behavior not as 
criminal offenders but primarily as suffering from a health disorder eases their access to 
health and social services.  
Interaction with the criminal justice system can be turned into an opportunity to encourage 
the voluntary participation in treatment services for people with drug use disorders. It is 
therefore critically important to screen for individuals in need of drug treatment services and 
continuing care also in the context of the criminal justice system. With the exception of cases 
where the criminal justice system directly employs treatment specialists, it is sensible for 
clinically trained treatment professionals to first provide an assessment, while the criminal 
justice system would facilitate referral to the treatment service in the first place. Depending 
on the severity of the disorder, some people with drug use disorders who come into contact 
with the criminal justice system may require only a brief interaction with a treatment service, 
other cases will require long-term treatment. 
 
When individuals with drug use disorders have committed criminal offences, those offences 
may be related to the drug use disorders, such as to finance a drug purchase. The most 
effective intervention for such patients is the treatment of their drug use disorder; and the 
criminal behavior usually stops when the patient stops illicitly using drugs. In this situation, 
the offer of effective drug treatment is the best public health and public security response 
for individuals with a drug use disorder and related criminal offenses. The continued need 
for criminal justice sanctions, as applicable, may depend on the outcome of this treatment.  
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In other cases, the criminal offence itself may be unrelated to drug use; and the person may 
not meet the diagnostic criteria of drug dependence. In this situation, while schemes of 
treatment as an alternative may be less applicable, still any person using drugs or with a 
drug use disorders in contact with the criminal justice system would benefit from healthcare 
or social interventions as part or in conjunction with other applicable measures. 
 
4.4.4 Treatment models and methods 
 
Fundamental principles  
 
Assessment of drug use disorders should be done by someone with clinical training 
 
Assessment of drug use disorders needs to be conducted by trained personnel with a health 
background. The key issues to be resolved in the assessment are: 
- Is the person in need of any acute treatment, such as for drug withdrawal or psychosis? 
- Does the pattern of drug use fit the pattern of either harmful use or dependence? 
- Is the person interested in receiving treatment for drug use disorders? 
- What kind of treatments have they received in the past? 
- What range of treatment interventions are likely to be effective? 
- Of these treatment interventions, which would the person be interested in pursuing? 
- Are there concomitant medical problems (including psychiatric issues) that need to be 
taken into consideration? 
 
Justice and health authorities would jointly be able to evaluate if treatment could be applied 
as an alternative to conviction or punishment and which options are available and would 
best match the person under consideration taking into account both the offence committed 
and the healthcare needs. 
 
Screening and Assessment is the key to treatment matching  
Matching patients to treatment options has been shown to be a difficult science. A pragmatic 
approach would take into consideration the pattern of drug use and the degree of 
dependence, with non-dependence normally starting with brief psychosocial interventions 
with the full range of longer term treatment options for dependent drug use. Medication-
assisted treatment options, such as methadone and buprenorphine, are limited to opioid 
dependence. Antagonist treatment of opioid dependence such as with naltrexone, is often 
limited to highly motivated individuals with limited psychiatric comorbidity. Significant 
medical or psychiatric comorbidity requires a treatment setting where these issues can also 
be addressed. Past treatment performance can be a good guide to future treatment success.  
 
A clinician may after their initial discussion propose a range of treatment alternatives that 
are feasible, in line with the needs of the client, and with which the client is prepared to 
engage. Based on this list, and the availability of different treatment programmes, the court 
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may make one or more proposals to the offender,11 who then either agrees or disagrees, 
indicating a preferred option.  
 
Because much of the information used in the screening and assessment process is based 
on self-reporting, it is critical that collateral sources of information (e.g., drug test results) 
may also be obtained when making treatment placement decisions.  
 
Risk for Re-Offending Principle 
The most effective programmes are those that appropriately match the type of intervention 
to the individual patient. It is well established that programmes providing only sanctions or 
services and that are not based on the risk profile of the individual have little to no impact 
on outcomes; and in some cases, these services are associated with poorer outcomes than 
the untreated comparison groups. As a result of these findings, many criminal justice 
systems have decided to reserve the most intensive treatment options for individuals with 
the highest levels of recidivism risk. Likewise, allocation of treatment resources should be 
more heavily invested in intensive services for individuals with higher recidivism risk. In most 
cases, those with a low risk for recidivism are likely to remain low risk, regardless of whether 
treatment services are provided. 
 
Need Principle 
The Need Principle states that services for individuals in contact with the criminal justice 
system should focus on “criminogenic” needs, address behaviors and attitudes that are 
associated with recidivism, and focus on people, who are amenable to change as a result 
of targeted treatment services. Specifically, services should target changes in antisocial 
attitudes, feelings, and personal associations. Helping individuals improve self-management 
skills and gain prosocial skills have been shown to lead to better outcomes. Conversely, 
traditional treatment approaches that target general psychosocial constructs, such as trying 
to improve self-esteem without addressing the antisocial aspects of the personality, should 
not be a cornerstone of service delivery.  
 
The research in this area has shown that there are four general categories of criminogenic 
needs to be addressed: 1) the history of antisocial behavior, 2) antisocial personality 
patterns, 3) antisocial cognition, and 4) antisocial associations, with four additional areas 




                                            
11 As in the Tokyo Rules, persons in contact with the criminal justice system are referred to as “offenders”, irrespective 
of whether they are suspected, accused or sentenced. 
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Responsivity Principle 
Based on a comprehensive assessment of the individual (including an assessment of his or 
her learning style, level of motivation, gender, and ethnicity), a tailored treatment approach 
should be developed. For example, many individuals in the criminal justice system do not 
respond well to traditional didactic treatment approaches, therefore treatment services need 
to strive to include more visual-spatial approaches when delivering treatment content. 
Approaches exclusively based on a punitive approach, as well as those that lack structure, 
should be avoided.  
 
Equity of services 
The basic premise of the provision of health services in relation to the criminal justice system 
is that health services should be similar in type and scope to what is available at the 
community level. The decisions of criminal justice officials should not deprive a person of 
the right to access the needed health care and services.  
 
Linkage to services at the community level 
In addition to equity in services inside and outside prisons, there should be a linkage 
between the criminal justice system and community-based services to avoid interruption of 
services and to ensure a sustained quality and continuity of care.  
 
The structure of the treatment services 
Most programmes begin by providing individuals with highly structured treatment services, 
including a stringent toxicology monitoring, and over time reduce the intensity of services, 
as progress is made. Effective programmes implement a range of incentives and, to a lesser 
degree, sanctions to help shape the individual’s behavior. Rewarding positive behaviors, 
such as providing the individual with a certificate of completion, helps to reinforce continued 
positive behavior. The use of negative reinforcement need to be used far less frequently and 
administered in a timely and objective manner when used (e.g., immediate increase in the 
frequency of urine testing after a positive result is obtained). 
 
A wide network of services needs to be provided 
Given the multiple problems encountered by individuals with drug use disorders in contact 
with the criminal justice system, it is important that treatment programmes through their 
networks can adequately address additional needs of patients such as housing, 
employment, legal, financial, and family problems.  
 
A continuum of treatment that includes aftercare is necessary to sustain recovery 
To assure that the patient will not re-offend and not incur in illicit drug use, treatment should 
continue beyond the primary treatment episode (aftercare). Sustaining treatment benefits 
requires a continuum of care that is designed to assist an individual in transitioning from 
corrections-based services to community-based services. Without the continuation of 
services, treatment gains typically are diminished or lost. Unfortunately, there are many 
obstacles to providing ongoing care, such as: 1) lack of coordination between criminal justice 
practitioners and treatment providers, 2) absence of incentives and sanctions for individuals 
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to continue treatment following unsupervised release from prison settings, i.e. after having 
served their sentence, 3) lack of community-based treatment programmes, and 4) the fact 
that treatment providers often are inexperienced in treating individuals involved in the 
criminal justice system. 
 
Treatment as an alternative to imprisonment 
 
After years of increasing prison population, alternatives to incarceration should be explored 
as a means to reduce the prison population. One approach has been to identify individuals 
with drug use disorders fulfilling specified eligibility criteria and provide them with intensive 
court or community supervision as an alternative to imprisonment. This often includes 
requiring community-based treatment as a condition of supervision. This approach enlarges 
the sentencing options available to courts, and may contribute to keeping families and 
communities together. Non-incarceration approaches for appropriate cases of drug-related 
offences of a minor nature are specifically allowed under the international drug control 
conventions. 
 
Drug treatment courts 
Drug treatment courts are one approach to providing alternatives to incarceration for 
individuals who have serious drug-related problems. As a specialized branch of courts, a 
drug court is created within existing jurisdictions to oversee court-supervised treatment and 
community supervision. The structure and processes of a drug court may vary, but most 
require participants to complete random urine tests, attend treatment counselling, meet 
regularly with probation or court officers, and often participate in self-help groups.  
 
Drug courts aim to provide supportive environments where judges will reward, and 
sometimes praise, individuals for successful programme participation, while limiting 
“punishment” to those who do not comply. In some cases, the drug treatment court option 
is only available after a guilty plea; and therefore treatment may not always be immediately 
available for those in need. In most drug treatment court programmes, individuals who 
successfully complete the programme can avoid either part or the entirety of a sentence of 
imprisonment, and, in many cases, certain convictions (such as for drug consumption) can 
be removed from their record. 
 
Community corrections 
Community corrections is another alternative to imprisonment for individuals, who have 
serious drug use problems. Terms of supervision are placed on the individual with the threat 
that a violation could result in incarceration. In addition to taking random drug tests, being 
subject to home inspections, and not incurring in illicit drug use, supervision requirements 
may include participation in treatment services. For the most serious offenders, there may 
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be more intensive supervision, for example upon probation, which includes more frequent 
monitoring by law enforcement practitioners as well as more frequent required meetings. 
The use of “day reporting” is another option in which individuals must report to a location, 
such as a probation office, on a frequent (usually daily) basis. In some jurisdictions, there 
are treatment options dedicated to those under such intensive supervision, and day 
reporting supervision. Alternatively, “halfway houses” are provided when there is a need for 
intermediate housing during the transition from prison to the community. Individuals are 
required to remain within the halfway house when not at work, at court, or seeking medical 
treatment. Halfway houses typically provide 12-step (self-help) support groups and, in some 
cases, provide treatment options dedicated for those residing within the halfway house. 
 
Supervised community treatment 
Supervised community treatment refers to services provided to persons under court or 
community supervision. As described above, this can include drug treatment courts as well 
as different types of community supervision instead of imprisonment. In many cases, the 
offences committed by persons with drug use disorders may not give rise to imprisonment, 
and allow for  individuals to be placed directly under community supervision, with a 
requirement that they receive probation or court supervised treatment services. Persons 
under community supervision have continued access to alcohol and drugs in the community, 
and therefore are at risk of continued illicit drug use. Remaining in the community can help 
maintain positive family relationships and address negative relationships. 
 
Treatment interventions  
In general, treatment interventions should be the same as those options available to the 
general population (as described in prior chapters), with recognition for  the unique situation 
of individuals with drug use disorders facing imprisonment. Treatment interventions must 
always be voluntary and based on the informed consent from the patient. All persons who 
access services, including individuals under the supervision of the criminal justice system, 
should have the right to refuse treatment, even if this entails other custodial or non-custodial 
measures. 
 
1) Medication-assisted detoxification is often the first stage of treatment. If a correctional 
agency does not have in-house detoxification available, it is imperative that the 
individual be referred to outside medical services. Forcing individuals to go through 
withdrawal without medical attention is not only unethical; it can be dangerous to the 
person’s health and safety.  
 
2) Outpatient treatment can include periods of more intensive treatment followed by 
periods of less intensive treatment. This method of a “step down” in treatment 
intensity is particularly suited for those receiving intensive treatment services in 
prison and who upon return to the community still need treatment services though at 
lower levels of intensity. Decreasing intensity over time should be based on whether 
or not an individual is meeting the goals of treatment.  
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3) Residential treatment can be provided in dedicated units within a prison. Such 
programmes are particularly valuable when targeting specific high-risk populations, 
such as young offenders, women, and people with psychiatric disorders. Having a 
dedicated residential environment minimizes exposure to people, especially in the 
general prison population, who might victimize the individual undergoing treatment. 
This dedicated space also helps target the issues pertinent to the subgroup (e.g., 
addressing trauma among victimized women).  
 
Clients in residential programmes are expected to cooperate with each other and 
collaborate on daily chores like preparing meals and doing laundry. By modeling and 
teaching problem-solving, communication skills, goal setting, and working together, 
this can be a highly-effective comprehensive treatment approach for those individuals 
with a history of problematic drug use. This approach, however, should not stand 
alone; residential treatment should be followed by the offer of ongoing services after 
the residential treatment programme is completed.  
 
4) Therapeutic community (TC) is a model of residential treatment that can be adapted 
to a prison population and has been found to be effective in randomized controlled 
trials (Smith et al., 2006). Prison-based TC programmes should be located in a 
separate unit of the prison with the structure and services similar to comparable 
programmes outside the prison setting. Participation in this treatment should be 
voluntary, with inmates from the general prison population eligible to apply for 
admission. Some interventions that have been used in the TC have not been found 
to be effective in reducing recidivism or non-medical drug use and should be avoided, 
including ineffective approaches that typically incorporate a highly regimented, 
military-style schedule combined with confrontation, discipline, and behavior 
modification.  
 
5) Self-help groups provide critical support for individuals in recovery from alcohol or 
drug problems. Self-help groups (NA or AA) exist across many settings, including in 
prison and in the community. Because many are religious-based and may reject the 
use of medication-assisted treatment, it is important that these factors are considered 
before recommending or requiring an individual to participate in specific self-help 
groups. 
 
6) Pharmacotherapy can be among the most important elements of treatment for some 
substance use disorders. For example, methadone and buprenorphine are the 
standard of care in opioid use disorder, while other approaches such as detoxification 
followed by naltrexone can be effective in preventing relapse. Decisions to 
incorporate medication-assisted treatment as part of an overall treatment approach 
needs to be considered on an individual basis. Facing criminal charges should not 
be the sole justification for recommending medication-assisted treatment.  
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Note: To reduce the risk of opioid overdose after discharge from prison, persons with a 
history of opioid use, as well as their families and friends should be equipped with naloxone  
along with instructions/training on its use in the case of an opioid overdose.  
 
4.4.5 Specific requirements for treatment in prison settings 
 
Providing the best possible treatment for people in prison settings presents an array of 
complex issues, including logistical questions such as who should provide treatment, where 
it must be provided, and when it should be provided.  
 
One of the more complex issues relates to the appropriate staffing of treatment programmes. 
In some prisons, in-house staff members are trained to provide treatment services, while in 
other prisons, outside treatment providers are contracted to deliver services. These staffing 
decisions should be made with the aim of achieving the best outcomes at the lowest possible 
costs. In general, though, outcomes for patients will depend on the quality of services 
provided rather than on the affiliation of staff members.  
 
Ideally, those participating in treatment should be isolated from other incarcerated 
individuals in order to maintain a prosocial environment. Having individuals who are in 
recovery return to the general prison population can easily undermine the gains achieved 
while in treatment, given the negative climate that often exists within the general prison 
setting. When stand-alone treatment environments are not possible or available, efforts to 
minimize exposure to external risk factors should be made (e.g., such as having separate 
dining and recreation times). The amount of time remaining on a person’s sentence must 
also impact treatment decisions because an individual may be in the middle of treatment at 
the time of release. Agencies need to consider the amount of time an individual will be 
incarcerated and then require completion of assigned treatment services prior to release or 
ensure for the necessary continued treatment after release. 
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Chapter 5: Characteristics of an Effective System to Deliver 




An effective national system for the treatment of drug use disorders requires a coordinated 
and integrated response of many actors to deliver policies and interventions based on 
scientific evidence in multiple settings and targeting different groups at different stages with 
regard to the severity of their drug use disorder. The public health system is best placed to 
take the lead in the provision of effective treatment services for people affected by drug use 
disorders, often in close coordination with social care services and other community 




• evidence-based  
• diversified 
 
The availability of treatment services refers to the physical presence of services capable of 
treating patients with drug use disorders.  
 
The accessibility of treatment services refers to their reach or physical accessibility for the 
whole population. Treatment services must be located conveniently and in geographic 
proximity of public transport (including rural and urban areas). In addition, access should not 
be hindered because of attitudes towards certain population groups or other factors. 
 
The affordability of treatment services refers to patients and the treatment system. 
Treatment services should be affordable for patients from different socio-economic groups 
and levels of income. At the same time treatment systems need to be affordable for the 
health and social system in order to be sustainable. 
 
The evidence-based approach of treatment services guarantees the quality of treatment 
services. Given the overall limitations in funding available for the treatment of drug use 
disorders, treatment interventions should be based on scientific evidence and follow 
evidence-based guidelines.  
 
Treatment services should be diversified and offer different treatment approaches. Not one 
approach fits for all disorders and its various stages. Therefore a diverse range of 
interventions should be in place in various settings to address the needs of patients with 
drug use disorders adequately. As recovery remains the ultimate goal of all treatment and 
care services, sustained recovery management services should be an integral part of it. 
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Treatment system organization model 
Drug use disorders can be described on a spectrum from lower to higher severity and 
complexity. The ICD-10 (WHO, 2011) differentiates in the section on Mental and behavioral 
disorders due to psychoactive substance use (F10-F19) between acute intoxication, harmful 
use and dependence syndrome. Thorley (1980) differentiates in his model of drug use in a 
similar way between intoxication, regular or excessive use and dependence (Figure 1). Per 
the 2015 World Drug Report of UNODC, out of a total of 246 million people - slightly over 5 
per cent of those aged 15 to 64 years worldwide – who used an illicit drug, some 27 million 
are people with drug use disorders and almost half of whom are people who inject drugs 
(PWID)(UNODC, 2015).  
 
 
Figure 1 Thorley’s model of drug use 
 
When developing a comprehensive treatment system that wisely allocates available 
resources and responds best to patient’s needs, the key public health principle to apply is 
offering the least invasive intervention possible with the highest level of effectiveness and 
the lowest cost possible. This principle is important when designing or reviewing a treatment 
system taking into account the treatment standards described in this document.  
 
From a public budget perspective evidence-based treatment of drug use disorders is a smart 
investment, as the costs to treat drug use disorders are lower compared to the costs of 
untreated drug dependence (UNODC/WHO, 2009). The rate of savings to investments can 
exceed a ratio of 12:1 through reductions in drug-related crime and costs of criminal justice, 
law enforcement and healthcare (NIDA, 2012). 
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Overall, the intensity and level of specialization of services should be corresponding to the 
needs and the severity of the substance/ drug use disorders of patients. A patient who has 
taken drugs only once needs for example a different type of intervention and intensity of 
support than a patient with a long history of drug use and other related health and social 
problems.  
 
Investments of public funds should therefore be made according to the frequency of 
treatment services needed. As shown in the service organization pyramid (Figure 2), most 
treatment services are required at levels of lower intensity, which can prevent people from 
developing more complex drug use disorders if delivered. As services at levels of lower 
intensity are more required and usually less specialized and less costly, treatment systems 
designed in line with the service delivery pyramid are more cost-effective, given that services 
offered are based on scientific evidence. However, investments are often made to a very 
high degree in highly intensive and highly costly treatment services at the top of the pyramid, 
which leads to a situation where people with low severity end up in highly intensive treatment 
services without having the necessity. When the severity of the disorder does not match 
with the intensity of the treatment, outcomes are minimized and resources inefficiently 
distributed, which is not a good investment of public funds.  
 
   
 
 






Figure 1 Service organization pyramid 
As drug treatment services at the outpatient level are in general less interruptive for patients 
and less costly for the health system, they are recommendable from a public health 
perspective as long as outpatient treatment is conform to the severity of the substance/ drug 
use disorder and the needs of the patient. 
World Drug Report data show that a big gap exists globally between the number of people 
who want or could benefit from treatment for drug use disorders and the number of people 
who actually receive services (UNODC, 2015). The non-existence of services at the lower 
threshold and lower intensity (such as brief interventions at the primary health care level) 
may also lead to the inaccessibility of low-threshold services, so that people who use drugs 
only get in contact with the health system when they already developed severe drug use 
disorders instead of having received less intensive (and less costly) support in earlier stages 
of their disorder. Data shows that individuals are rarely screened by primary care 
practitioners (Ernst et al, 2007). However, providing screenings and initial services in 
primary healthcare settings is feasible and helps identify, support and refer people with drug 
use problems, therefore contributing to reduce health-care costs.  
 
Suggested interventions at different service levels 










Screening, brief interventions, basic health care, referral 
Continued support to people in treatment/contact with a 
specialized treatment service 






Unconditional social support 
Ensuring access to more specialized health and social 
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Relapse prevention 




Mental health treatment 
Internal medicine 
Dental treatment 




Family support and reintegration 
Vocational training/Education programmes 
Income generation/micro-credits 
Leisure time planning 







Life skills training 
Ongoing therapeutic support 
Recovery management services 
 
 
An important decision when involved in the planning of a functional and sustainable drug 
dependence treatment system is related to the allocation of resources and the services 
offered at different levels of the health and social system. Treatment systems should be 
designed using available data on drug demand and supply at various levels as an important 
guidance (UNODC, 2003). The non-availability of data or systematic data collection systems 
should not be an obstacle for the implementation and delivery of drug dependence treatment 
and care services. Especially, because some of the indicators, such as the Treatment 
Demand Indicator (“service utilization for drug problems”), can only be effectively collected 
if drug treatment services are in place that can collect patient level data. 
 
The development of a functional national drug information system needs support from 
partners at all levels and different sectors, as it involves not only a technical component but 
also a participatory process to agree on governing policies of a national drug information 
system and a national drug observatory. A step by step guide on this process is available 
for reference (EMCDDA, 2010). 
 
Treatment service organization model: One-stop-shop approach for the treatment 
and care of drug use disorders 
Given the diverse and multiple needs of people with drug use disorders, ideally a wide range 
of medical and social services should be provided in one facility or programme, which can 
be described as a “one-stop-shop” (Figure 3). Such an integrated service provision without 
barriers in accessibility includes the full range of care services and provides drug users with 
a comprehensive drug dependence treatment (Rapp et al, 2006).  






Figure 3 One-stop-shop approach 
 
Treatment service organization model: Community-based approach for the treatment 
and care of drug disorders 
 
If treatment programmes cannot integrate all services (like the one-stop-shop approach) a 
coordinated comprehensive continuum of care, including various components of the care 
system, should be developed. This approach positions clinical services as a core element 
but offers many auxiliary services at the municipality/community level, which share a 
perspective and work in close coordination with established referral mechanisms. In order 
to ensure access, low-threshold entry level services (e.g., outreach, drop-in) with defined 
referral mechanisms to clinical treatment services and accompanying social services should 
be in place.  
 
In a community-based treatment network (Figure 4) broad partnerships exist not only 
between different services from the public health and public social sector but also with other 
community stakeholders. To coordinate all services provided it is beneficial to develop a 
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available in the community. Community-based treatment services offer a multifactorial and 
multi-sectorial approach to manage drug-related problems and health issues. Such an 
approach encourages the use of a variety of paths to treatment, recovery and increased 
quality of life. Partners in a community-based network of services need to work in close 
collaboration and coordination to provide the best possible support through effective referral 
and case management strategies in order to guarantee a continuum of care. Community-
based treatment networks provide a range of low-threshold entry points and ease access to 
different treatment and care services. 
 
 
Figure 4 Model of community based treatment 
 
Key principles of community-based drug dependence treatment and care include:  
• Continuum of care from outreach, basic support and reduction in the harms related 
to drug use to social reintegration, with no “wrong door” for entry into the system 
• Close collaboration between civil society, law enforcement and health sector 
• Minimal disruption of social links and employment 
• Integrated into existing health and social services 
• Delivery of services in the community – as accessible as possible to drug users  
• Involvement and building on community resources, including families 
• Participation of people who are affected by drug use and dependence, families and 
the community-at-large in service planning and delivery 
• Provision of evidence-based interventions 
• Informed and voluntary participation in treatment 
• Comprehensive approach with a recovery perspective that takes into account various 
needs (health, family, education, employment, housing)  
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• Acceptance that relapse is part of the treatment process and that individuals can re-
access treatment services 
• Respect for human rights and dignity, including confidentiality 
 
Health services such as primary health care services, specialized drug treatment services, 
hospitals and clinics and social services are key partners in a community-based treatment 
and care network. In addition, broader partnerships should also be formed with other 
community stakeholders such as 
• Civil society/NGOs (e.g., providing outreach services, vocational training, aftercare 
activities) 
• Police (e.g., screening, referring to health system) 
• Criminal justice system (e.g., providing treatment in prison, arranging follow-up 
services in the community) 
• Professional organizations (e.g., providing legal support) 
• Trade and services establishments (e.g., creating vocational opportunities) 
• Organized groups of drug users and people in recovery 
• Organized groups who identify themselves based on gender and ethnicity 
• Educational and research institutions 
• Youth organizations and youth leaders 
• Religious organizations (e.g., offering places for overnight stays) 
• Religious and community leaders 
• Neighborhood associations  
• Family members 
 
To ensure that patients are linked and referred to appropriate services that suit their needs, 
case management is an essential component. Case managers work together with patients, 
members of the treatment team, and services or organizations to select the best combination 
of interventions and support. Case manager also provide a continuous assessment of the 
treatment progress. In this way case management ensures that the network of referral and 
other support services remains accessible and that resources are utilized efficiently. The 
following chart depicts a functioning case management system from the perspective of 
people who use drugs and enter the treatment system. There is “no wrong door” for entry 
into the system, as different treatment services are connected and collaborate, so that 
patients can be referred to the service facility which corresponds to the severity of their 
disorder and their individual needs.  
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Figure 5 Model of case-management and treatment and care for people who use drugs and 
are affected by drug use disorders 
 
UNODC has published a good practice document on community-based drug dependence 
treatment (UNODC, 2008) and a guidance note (UNODC, 2014) on the same topic, which 
provide examples from around the world and detailed practical guidance on the elements of 
a community-based treatment network. 
 
The continued treatment service model: Sustained Recovery Management 
Recovery is considered to be “[…] a continuum process and experience through which 
individuals, families, and communities utilize internal and external resources to address 
substance use disorders, actively manage their continued vulnerability to such disorders, 
and develop a healthy, productive and meaningful life” (Adapted from W. White, 2007). 
Recovery should be an ultimate goal at every stage of the treatment continuum, at every 
stage of the disorder and across a variety of settings (Table “Suggested interventions at 
different service levels”), from outreach, basic support and reduction in the harms related to 
drug use and to social reintegration. A continuity of services needs to be ensured in order 
to support people with drug use disorders and emphasize the need for rehabilitation, 
reintegration and the recovery itself. Such services that can be called “sustained recovery 
management services” might be already integrated in a functional community-based drug 
dependence treatment and care network. The utilization of the existing services will be lower 
as individuals progress towards a sustained recovery. Such services (like any other drug 
dependence treatment service outside of life-endangering emergency situations) should be 
voluntary and have the aim to be the least disruptive for the person in recovery. Despite 
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recovery being the ultimate goal of treatment, it is important to recognize that drug 
dependence is a chronic disorder and that it is likely that patients relapse and reuse the 
network of treatment services again. 
Recovery services can be implemented in a range of settings and stages of the disorder and 
include for example resolving of legal issues, income generating activities, peer recovery 
support, social support, aftercare, half-way houses, vocational training, or other. In the 
UNODC (2008) good practice document on sustained recovery management, eight domains 
of recovery capital have been defined as a suggestion for areas and interventions to be 
considered on a continuing basis (Figure 5). 
 
 
Figure 5 Essential supports for achieving rehabilitation and social reintegration 
 
Recommendations/Summary 
• In a treatment system resources should be invested where they are most needed. A 
focus should be on low-threshold and easily accessible treatment and care services 
as a first step. 
• All treatment services provided should be affordable and evidence-based and 
delivered with recovery as the ultimate goal integrating sustained recovery 
management into all treatment and care services. 
• Available data should be used when designing and implementing a drug dependence 
treatment system. However, the non-availability of data should not be an obstacle for 
the implementation and delivery of drug dependence treatment and care services. 
• A one-stop-shop approach (a full range of care services available in one facility or 
programme) or an integrated network of health and social services in the community 
are models to deliver an accessible and diversified continuum of care for drug use 
disorders. 
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